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ABSTRACT 
Neural progenitor cells (NPCs) have the potential to be used as a cell based therapy to treat Alz-
heimer disease, spinal cord injury and other significant damage to the central nervous system.  In 
order to utilize the therapeutic potential of NPCs, we must first learn to control their migration, prolif-
eration, differentiation and growth.  An ideal methodology would entail directed stem cell migration to 
damaged tissue; proliferation until the target is reached; differentiation into the most beneficial pheno-
type; and integration of cells into the existing tissue.  A myriad of stimulants that alter NPC behavior, 
exist in vivo.  Characterizing the individual contributions of each stimulant or cue in vivo can be diffi-
cult to deconvolute, unless discerned in vitro.  We investigate several of these cues individually and 
synergistically.  We focus on the influence of extracellular matrix proteins, components secreted from 
surrounding cells in the central nervous system (i.e. - astrocytes, microglia) and the physical micro- 
and nano-architecture surrounding NPCs.  One other stimulus that has not been explored much, but 
is investigated here extensively, is the influence of electric fields that mimic the electric gradient exis-
tent in the developing and adult nervous system.  We investigate the contribution of electric fields as 
stimuli to NPCs and the possible use of electric fields to reap the therapeutic potential of NPCs.  In 
summary, investigation of the influence of a synergistic combination of external cues on the behavior 




   
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1. Dissertation Organization 
This dissertation is organized into five chapters.  The first chapter is an extensive literature review 
which includes fundamental knowledge used in undertaking the research presented in following chap-
ters.  In part, the first chapter is modified from a recently published book chapter1.  First, basic knowl-
edge of stem cell research is provided.  Second, insight into the relationship between soluble and 
insoluble proteins or electrical stimulation and the proliferation, growth and differentiation of NPCs is 
given.  In brief, the importance of cell to cell, cell to substrate, and cell to extracellular matrix interac-
tions are reviewed.  Then, bioelectricity, the therapeutic use of electrical stimulation, and the complex-
ity of investigating electrical stimulation of mammalian cells in vitro, ends the first chapter.  In general 
the first chapter conveys that physical, biological, chemical or electrical cues found extracellularly can 
alter cellular behavior. 
The second, third and fourth chapters are original articles that have been or will be submitted to jour-
nals.  In the first of these three, we rigorously investigated the use of multiple extracellular matrix pro-
teins individually or combined with biological soluble factors and microscale substrate architecture on 
the behavior of NPCs.  In the third chapter, the use of nanoporous or nanoscale topography as a 
means to control NPCs was investigated.  Finally in the last journal article, the use of electric fields to 
control NPC behavior was investigated.  The one common aspect of NPCs that was assayed was 
differentiation into the three possible phenotypes in the central nervous system.  However, other as-
pects of NPC behavior were also investigated to determine the response to external cues.   
Overall conclusions from this research are presented in last chapter.  Some possible future directions 
are presented as an important aspect of achieving further progress related to the control of stem cells 
in vitro for cell based regenerative approaches.   
1.2. Stem Cells 
In 1960, stem cells were first acknowledged by Till, Becker and colleagues who observed single cells 
in the bone marrow of mice that gave rise to blood cells, in vivo 2, 3.  Broadly, stem cells have three 
properties that distinguish them from other cells: they are capable of dividing and renewing for long 
periods; are unspecialized (potential); and give rise (differentiate) to more committed or specialized 
cell types. 
1.2.1. Stem Cell Potential 
An uncommitted or unspecialized cell is one that does not perform any tissue-specific function.  When 
stem cells differentiate they produce cells with lower potential or cells that are more committed, until a 
final functional cell fate is reached (Figure 1.3).  A mammal is produced from the most potent or toti-
2 
   
potent stem cell: a fertilized egg.  Thus, a totipotent stem cell is one that can create an entire organ-
ism.  The progeny of the zygote are totipotent after cleavage, up to the formation of the morula (5 cell 
divisions of the zygote) 4.  Totipotent stem cells differentiate into pluripotent stem cells, which have 
the ability to produce tissues from the three embryonic germ layers (ectoderm, endoderm, and meso-
derm).  In other words, pluripotent stem cells eventually form tissues within the body but not those of 
the placenta.  Embryonic stem cells are pluripotent stem cells.  Further differentiation leads to an 
increase in committed cell fate, giving rise to multipotent stem cells.  Multipotent stem cells differenti-
ate into cells of a specific tissue or cell lineage (e.g. hematopoietic stem cells differentiate into red 
blood cells, white blood cells, platelets, etc.).  Finally, unipotent stem cells only produce one cell type 
but can self-renew which separates them from non-stem cells. 
1.2.2. Progenitor Cells 
Further differentiation of multipotent or unipotent stem cells produces progenitor cells, which are simi-
lar to multipotent or unipotent stem cells except that progenitor cells have limited self-renewal and 
differentiation capacity.  Progenitor cells can produce cells of a specific cell lineage but not indefi-
nitely, instead progenitor cells go through several rounds of division before terminally differentiating 
into a cell fate.  In other words, progenitor cells are more committed to a final cell fate than multipo-
tent or unipotent stem cells. 
1.2.3. Embryonic Stem Cells 
Figure 1.1.  Embryonic stem cells are derived from the inner mass cells in an embryo.  Illustrated by 
the University of Kansas Medical Center, Center for Reproductive Sciences Cell Imaging Core5 
About five days after an egg is fertilized, it develops into a ball of about 30 -150 cells called a blasto-
cyst.  The blastocyst can be divided into three structures: the trophectoderm, which is the layer of 
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cells (in this case called trophoblast) that surrounds the blastocyst and is responsible for negotiating 
implantation, developing into the placenta, and controlling the exchange of oxygen and metabolites 
between mother and embryo; the blastocoel, which is the hollow cavity inside the blastocyst; and the 
inner cell mass, which is a group of approximately 30 cells at one end of the blastocoel.  Embryonic 
stem cells are obtained by removing the inner cell mass and proliferating these cells in culture (Figure 
1.1).  As mentioned, embryonic cells are pluripotent, producing germ layer tissues, but not those of 
the placenta, as the trophoblast develops into the placenta.  Embryonic stem cells have been shown 
to proliferate for approximately a year or more in culture.   
1.2.4. Sources of Embryonic Cells 
One source of embryonic stem cells is in vitro fertilization, where a couple may decide to donate their 
unused fertilized eggs, for research purposes.  Another potential source might be created by remov-
ing and replacing the nucleus of an unfertilized human egg cell with the nucleus of a cell from another 
person (therapeutic cloning).  This process yields a blastocyst from which stem cells can be ex-
tracted.  This may lead to embryonic stem cells that would be compatible with the person who needs 
treatment.   
1.2.5. Concerns of Stem Cell Use 
The use of embryonic stem cells is highly controversial because the embryo dies after the inner cell 
mass or stem cells are removed.  Whether interfering with the development of a potential human life, 
is appropriate is a question of much debate.  There are many profound view points, but they will not 
be covered in this report.   
However, methods for keeping the embryo alive after embryonic stem cells are removed are being 
developed.  The first successful trials were in rats and later with human embryos6.  Some embryos 
developed into normal rat pups, other embryos did not survive the procedure.  Therefore, the removal 
of the inner cell mass is still detrimental to the embryo.  The technique must allow all embryos to sur-
vive stem cell removal, and develop without abnormalities for the use of embryonic stem cells to be 
less controversial.  However, this technique may not be developed fully because of the possibility of 
creating an unhealthy human. 
Recently, exciting developments could potentially eliminate the need to derive stem cells from the 
embryo.  Researchers at Kyoto, University have developed a promising technique which induces 
adult skin cells (dermal fibroblasts) to become pluripotent cells 7.  The induced pluripotent stem cells 
(iPS) were found to differentiate and behave as embryonic stem cells.  Additionally, iPS would greatly 
reduce the risk of patient rejection because iPS would be derived from the patient’s skin and would 
contain a matching genetic code. 
Even if the ethical controversy is resolved, the International Society for Stem Cell Research has 
stated that the use of embryonic stem cells can be dangerous.  This is due to the rapidly dividing and 
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unspecialized nature of embryonic stem cells.  If implanted, stem cells may proliferate into a tumor, 
instead of differentiating and integrating into the surrounding or damaged tissue.  Thus, the tremen-
dous therapeutic potential of stem cells will not be used effectively until they can be completely con-
trolled. 
1.2.6.  Adult Stem Cells 
Adult stem cells compared to embryonic stem cells, have decreased differentiation potential (multipo-
tent or unipotent), and do not survive as long in vitro.  Adult stem cells are often named after the tis-
sue in which they are found or the cells that they produce.  For example, some stem cells found in 
bone marrow are called hematopoietic (of the blood) stem cells because they produce all blood cell 
types.  Another example are the stem cells found in central nervous system niches called neural 
stem/progenitor cells (NSCs or NPCs) as seen in Figure 1.3.  NPCs differentiate into cells of the nerv-
ous system as their final cell fate 8-11.  Other locations where adult stem cells have been found are 
hair follicles 12, skeletal muscle 13, the liver 14, the epidermis 15 and the heart 16.  Furthermore, tissues 
in which adult stem cells are found continue to increase.  In short, embryonic stem cells are involved 
in the development of an organism and adult stem are involved in maintenance, repair and cellular 
replacement during normal cellular turnover. 
1.2.7. Adult Stem Cells vs. Progenitor Cells  
Progenitor cells also give rise to cell types belonging to specific lineages (i.e.-hematopoietic) and are 
similar to adult stem cells but have limited self-renewal.  The distinction between adult and progenitor 
cells can be confusing because of the criteria used to define a stem cell.   
Neural stem/progenitor cells found in the hippocampus are cells whose definition is somewhat un-
clear due to contradicting classifications.  Some groups have classified these cells as progenitors and 
others say that they are stem cells 17.  One recent study suggests that the cells found within the hip-
pocampus are progenitor cells that arise from true neural stem cells found in a layer surrounding the 
hippocampus 18.  Additionally, the ambiguous use of “adult stem cell”, “progenitor”, and “precursor” 
has led to skewed classifications. 
To summarize, adult stem cell are proliferative, capable of long-term self-renewal (throughout the life 
of the animal) and multipotent; generating a large population of progeny that can terminally differenti-
ated into the cell types of the tissue in which they are found.  Thus, NSCs and NPCs are present in 
the brain throughout life and give rise to new neurons, astrocytes, and oligodendrocytes, just as in the 
prenatal or developing brain.  However, NPCs do not self-renew indefinitely. 
1.3. Cells in the Nervous System 
The central nervous system (CNS) is comprised of two types of cells; neurons and glia (please refer 
to Figure 1.2 for the following).  There exist 10 to 50 times more glial cells than neurons in the CNS of 
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vertebrates.  Glial cells provide support and structure to the CNS; insulate axons with myelin; perform 
housekeeping duties regularly and during injury; guide migrating neurons and direct the outgrowth of 
axons in development; regulate presynaptic terminals at the nerve-muscle junction, and more.  Not 
forgetting that neurons have subcategories, the glial cells within the nervous system are also further 
categorized into macroglia and microglia.  Macroglia, are further subcategorized in the CNS into oli-
godendrocytes and astrocytes, and in the peripheral nervous system (PNS) into Schwann cells. 
 
Figure 1.2.  Central Nervous System Cells modified from 19 
First, microglia, as the name implies, are typically much smaller than the cells found in the CNS and 
are the smallest of the glial cells.  Microglias are phagocytes produced outside the nervous system 
and are unrelated physiologically and developmentally to the other cells of the CNS.  The brain owes 
its limited immunological response to the capability of microglia to remove apoptotic cells and debris.  
Phagocytosis by microglia (engulfing/eliminating waste or cell debris) is induced when mobilized or 
activated, because of injury, disease, or infection of the nervous system. 
Second, oligodendrocytes in the CNS and Schwann cells in the PNS are responsible for making the 
transmission of neuronal signals more efficient.  They do this by insulating axons with sheaths of a 
lipid-based substance called myelin.  The sheaths are created by oligodendrocytes/Schwann cells 
densely wrapping their membranous processes around the axon repeatedly.  A single oligodendro-
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cyte myelinates an average of 15 internodes/axons, while a single Schwann cell, only envelops one 
internode/axon.  The myelin produced by Schwann cells are similar, but chemically distinct, from that 
produced by oligodendrocytes. 
Lastly, astrocytes derive their name from the Greek word astron which means of the stars.  The rea-
son for this name is easily understood when observing astrocytes through a microscope in cell cul-
ture, where astrocyte morphology resembles stars.  Astrocytes are the most numerous cells in the 
CNS and were once consider solely supportive cells.  Astrocytes filter nutrients to neurons, having 
end-feet at both capillaries and neurons.  These end-feet encircle capillaries in the brain helping 
make an impermeable barrier that prevents blood from entering the brain, know as the blood-brain 
barrier.  Neurotoxic substances and high concentrations of neurotransmitters such as norepinephrine 
and glutamate are prevented from entering or accumulation in the brain, by the blood-brain barrier. 
Astrocytic functions are indispensable for the maintenance and survival of neurons.  Yet, astroglia are 
more than mere “support cells” for neurons, as once believed.  Glial cells in the CNS are now known 
to serve a more profound role due to the discovery of neurogenesis 20.  In neurogenic niches, NPCs 
are influenced by proteins that originate from astrocytes and other glia.  Thus, glial cells create the 
proper environment for NPCs to proliferate, differentiate and integrate into the preexisting nervous 
system; making glial cells more than just neuronal “support cells”.  
1.4. Neural Progenitor Cells 
NPCs are present in the adult nervous system throughout life, can self-renew, but not indefinitely, and 
give rise to (differentiate into) cells of the nervous system (neurons and glial cells) 8-11 (see Figure 
1.3).  In the adult CNS, differentiation occurs in specific niches. Some locations where NPCs are 
found within the adult nervous system are the olfactory bulb 11, 21, hippocampus 22, sub ventricular 
zone 23 and spinal cord 24-26.  The research performed in our group characterizes the behavior of 
NPCs from the hippocampus of rats and humans in the presence of different cues or stimuli. 
1.4.1. History of Postnatal Neurogenesis 
Neurogenesis is the process of generating functional neurons from progenitor cells.  This process 
includes proliferation and neuronal fate specification of neural progenitors, and maturation and func-
tional integration of neuronal progeny into neuronal circuits.  Originally it was thought that neurogene-
sis in mammals only occurred in early developmental stages 27.  In 1913 Santiago Ramon y Cajal 
determined that neurons were generated only before birth 28.  Limited laboratorial techniques pre-
vented successful investigations into speculations of dividing cells in the postnatal CNS.  Thus, 
Ramon y Cajal’s work became a dogma for about 90 years despite evidence that began to prove 
otherwise starting in 1961. 
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Figure 1.3.  Neural Progenitor Cells reprinted from8 with permission from AAAS 
In 1959, a technique to label proliferating cells was developed using the radio labeled nucleoside, 
tritiated-thymidine (3HT).  3HT incorporates into replicating DNA during the S-phase of the cell cycle 
and is detected with radiography.  So, 3HT positive cells in radiographs of tissue section would indi-
cate that those cells were mitotic after the addition of 3HT.  In 1961, Altman and colleagues detected 
3HT in radiographs of three-day postnatal mice brains 29.  Soon after, 3HT evidence in other regions 
of adult rats brains, such as, the neocortex 30, olfactory bulb 31 and dentate gyrus of the hippocampus 
32 were published.  Yet, adult neurogenesis was not accepted by the scientific community.   
It is somewhat puzzling that these discoveries did not begin to dissolve the dogma against neuro-
genesis.  There are several reasons for the dismissal of Altman’s discoveries.  First, cells with 3HT 
positively labeled nuclei were not easily distinguishable as neurons; radiolabeled cells could be divid-
ing glial cells.  Second, 3HT also incorporates into DNA when it is repaired, therefore neurons could 
have been labeled during DNA repair.  Third, the findings suggested migration from the ventricle to 
other parts of the brain such as the olfactory bulb which was considered very unlikely.  Lastly, another 
possible reason was that Altman was a self-taught post doctoral fellow researching at MIT.  Thus, 
neuroscientists would not go against Ramon y Cajal’s almost undisputed reputation without further 
proof.   
From a spatial and mechanistic perspective, it seemed rather implausible for neurons to seamlessly 
integrate into the adult brain.  How could each new neuron, integrate into the existing neuronal net-
work without disrupting existing connections and accommodate itself in an already dense tissue (the 
brain)?  Furthermore, the source of new neurons remained a mystery.  It was unlikely that adult neu-
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rons, some containing dendritic branches with many connections would retract all it’s projections to 
become mitotic.  Therefore, skepticism remained toward neurogenesis. 
Sixteen years after the initial discovery of neurogenesis, further proof was demonstrated.  In 1977, 
Kaplan & Hinds found newborn neurons in the hippocampus were still alive after 30 days 33.  Later, it 
was shown that new neurons received synaptic inputs 34 and extended axons to targeted areas 35.  
These findings showed that new neurons served a long term purpose and could integrate into a pre-
existing neural network without detrimentally disrupting that network. 
Much later, a very important study of the telencephalon (brain region) in songbirds related neurogene-
sis to learning 36.  Increases in postnatal neurogenesis along with the replacement of neurons coin-
cided with increased knowledge or information gain.  This was seen in canaries, which during the fall 
learn a new song and experience increased neurogenesis and replacement of dead neurons in the 
high vocal center of the brain.  The song is used 8 months later during the matting season and the 
neurons acquired in the fall are not replaced.  However, neurons created during the spring do not re-
main for so long and are replaced.  Such evidence indicates a possible hierarchical selection process 
of neuronal replacement.  In this manner the brain may balance limited space with the storage of 
important knowledge.   
In 1982 an improved method to detect neurogenesis was successful in mice.  The use of bromode-
oxyuridine (5-bromo-2-deoxyuridine, BrdU), analogous to 3HT, as a S-phase indicator, eliminated the 
need for radiographs making the analysis faster 37.  Additionally, with every cell division, the con-
centration of BrdU halves within the cell, leading to a lower intensity, which provides a quantifiable 
method for determining rate of cell division and the amount of cell divisions taken by a cell to obtain a 
non-mitotic or completely differentiated state.  Furthermore, BrdU can be combined with immunocyto-
chemistry to identify the final fates of differentiating stem cells.  In humans, proof of neurogenesis was 
shown using BrdU combined with one of the neuronal markers, NeuN, calbindin or neuron specific 
enolase as the assay 38. This method is the most widely used and accepted technique to identify adult 
neurogenesis and isolate NPCs from the brain. 
The mechanistic issue of accommodating and producing neurons was solved with the discovery of 
NPCs.  The isolation of NPCs proved that in the CNS new neurons were being created from undiffer-
entiated cells and not from pre-existing neurons.  The first area of the brain where this was shown 
was the subventricular zone 39, followed by the dentate gyrus of the hippocampus 22, 23.   
Functional purpose to new neurons has been strongly shown in electrophysiological studies. Synaptic 
activity and integration into preexisting neural networks has been shown in the CNS, specifically in 
the olfactory bulb 40, 41.  Using combined retroviral-based lineage tracing 42 in the developing nervous 
system with electrophysiological studies (i.e.- patch clamping), newborn neurons have been shown to 
functionally and synaptically incorporate into the adult CNS 41, 43, 44.  
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Now, the challenge lies in understanding why neurogenesis occurs only in certain areas of the brain, 
what functions this process serves, and how this processes can be exploited to develop a therapeutic 
approach to damage in the CNS. 
1.4.2. NPCs in the CNS 
Within the brain, there are two zones which are most proliferative or neurogenic: the subventricular 
zone (SVZ) of the lateral ventricles, and the subgranular zone (SGZ) of the dentate gyrus in the hip-
pocampus 45, 46.  The SVZ and SGZ, as well as other areas with NPC activity, serve as models for the 
study of neurogenesis in vivo because of migration, differentiation and maturation of NPCs.  These 
areas are interesting because the mature daughter progenitor cells that arise from asymmetric cell 
divisions, in both the SVZ and dentate gyrus of the hippocampus, migrate to distinct targeted areas 
as they mature.  At the targets, the progenitor cells may completely differentiate or become quiescent 
47.  Cellular signaling occurs throughout this process.  Thus, within these niches lie guidance, fate 
specific and proliferative cues that control NPC behavior.  Suspected cues are studied by purifying 
and maintaining NPCs in vitro from these neurogenic niches, as demonstrated by Palmer et al. for 
hippocampal NPCs 48. 
However, the SGZ and SVZ are not the only regions in the CNS where NPCs reside.  Since, cells 
found in non-neurogenic regions, such as the spinal cord 49 can produce neurons when dissected and 
transplanted into neurogenic regions, such as the dentate gyrus 50.  It seems that quiescent NPCs are 
found throughout the CNS.  These dormant NPCs differentiate only when given the appropriate sig-
nals or cues, in vivo or in vitro, as demonstrated by Jia and Chen.  Some of these signals originate 
from neurogenic-niche astrocytes (neonatal brain, adult SGZ and SVZ) and include sonic hedge hog 
(SHH) 51. 
The exact phenotype of the adult neural stem cells (least differentiated with indefinite self-renewal) in 
the CNS, has not been clearly established.  Some evidence indicates that a subpopulation of ependy-
mal cells in the lining of the third ventricle are stem cells 52.  More convincing evidence points to a 
subset of cells in the SVZ that are astrocyte-like (GFAP expressing) as being adult stem cells 53, as 
described in a recent review by Alvarez-Buylla 54 and in a recent article by Jiao 51.  The resolution of 
this issue is crucial in understanding neurogenesis and the development of cell based therapies for 
the nervous system 54, 55. 
1.4.3. NPC Fate Identification 
NPCs studies usually require differentiated cells to be identified phenotypically and detected among 
cells that did not originate from NPCs.  The phenotypes of differentiated can be identified with immu-
nocytochemistry (ICC) and fluorescence microscopy.  To distinguish NPCs and their progeny, 
retrovirus or transgenic mice can be used to produce NPCs that express fluorescent proteins, such a 
green fluorescent protein (GFP).  The expression of the fluorescent proteins is tailored to be ubiqui-
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tous in NPCs, making NPCs easily distinguishable from other cells, with a fluorescent microscope, 
when co-cultured with non-fluorescent cells.   
In ICC, antibodies with specific antigenic targets are used to identify proteins that are unique to cer-
tain cell types.  These antibodies are tagged with fluorescent probes that when exposed to a specific 
excitation wavelength(s) emit light allowing the probes to be visualized.  Wherever the cell-type-spe-
cific protein, identified by the antibody, is found fluorescent light will be detected.  This does not 
conclusively prove that the cells identified are of a specific type, unless their functionality is tested.  
However, this method is used most researchers to determine stem cells have differentiated into. 
The proteins (antigens) or antibodies commonly used to identify cells that differentiate from NPCs in 
the research presented here are listed in Table 1. 
Table 1.1 – Antibodies used to Identify Cell Type of Neural Cells 
Cell Type  Antibody  Antibody Description 
Progenitor  Nestin  
    
Intermediate filament protein expressed in both neuronal 
and glial progenitors 
Neuron  TUJ1  Antibody against of class III b-tubulin (in early neurons) 
  MAP2ab  Antibody against microtubule associated protein 2ab (in 
mature neurons) 
Astrocyte  GFAP  Antibody against glial fibrillary acidic protein 
Oligodendrocytes  RIP  
    
Recognizes 2',3'-cyclic nucleotide 3'-phosphodiesterase 
(CNP), a known non-compact myelin protein 
1.5. Control of Stem Cells and Therapeutic Applications 
Since stem cells were first discovered in bone marrow, it is not surprising that these cells were the 
first used clinically.  Bone-marrow transplants and peripheral blood transfusions (which contain stem 
cells) are still used to treat leukemia and inherited blood disorders 56.  Stem cells have also been 
used to treat severe autoimmune disease 57 and repair cartilage 58, cardiac muscle 59, liver tissue 60 
and other tissues.  Thus, the discovery of stem cells in adults may provide a regenerative cell based 
therapy for the tissue in which they are found.   
Currently, NPCs are one of the most investigated progenitor cells because of their ability to produce 
neurons and the demand for a bioengineered solution to neurodegenerative diseases and nervous 
system injury 11, 21, 61, 62.  For example, neurons lost due to Parkinson’s or Alzheimer’s diseases may 
potentially be replaced using NPCs.  Additionally, the delivery of stem cells into the retina to treat reti-
nal disease, such as Macular Degeneration, is being investigated 63.  First, however, stem or progeni-
tor cells must be completely understood to be used as an effective therapy.   
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Figure 1.4.  GFP expressing NPCs implanted into the developing retina 63.  Used with permission 
from Blackwell Publishing Ltd.  
One aspect of stem cell behavior that must be carefully characterized is the adoption of a final cell 
fate.  Stem cell fate is dependent on both intrinsic (e.g. - epigenetic factors) and extrinsic signals that 
alter the adoption of a cell fate 64.  The dependence on the surrounding environment has been shown 
in many in vivo transplantations.  For example, NPCs transplanted into the developing eye of a rat 
can migrate, integrate, and adopt similar morphology of adjoined but distinct cell layers in the retina 
(Figure 1.4) 63.  Thus, instructive signals reside within each tissue, that dictate where stem cells 
should migrate and what they should differentiate into.   
Determining the cues that allow or prevent stem cell migration and integration into tissues is crucial 
for the advancement of cell-mediated therapies and cellular biology.  If stem cells cannot be con-
trolled in vivo, adverse effects, like the formation of teratomas, can arise when applied therapeutically.  
In clinical trials, fetal neural tissue implanted into patients with Parkinson’s disease alleviated the 
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symptoms of some patients 65; yet, the inability to control stem cell behavior exacerbated the symp-
toms of others 66, 67.  Thus, if we are to overcome our limited ability to treat damage to the CNS, using 
stem cells, we must first completely learn to control stem cells or NPCs 55, 68.  Additionally, under-
standing the processes that occur in the diseased or injured CNS is necessary for cell-based 
therapies to overcome our limited therapeutic capability.   
In order to control and apply stem cells therapeutically, we must consider all reasonable external 
interactions that occur in the stem cell niche and areas into which they are transplanted.  This is quite 
a daunting task, considering the thousands of possible external interactions that any cell can have.  In 
general, signaling proteins can originate from other cells, or in self-regulation are secreted by stem 
cells themselves.  Furthermore, extracellular matrix molecules also interact with stem cells to alter 
their behavior. 
1.6. The Extracellular Matrix 
The ECM is a structural component of every tissue composed of molecules secreted by resident 
cells.  The distinct physical properties of tissues are due to variations in the ECM composition (i.e.-
bone compared to skin).  Broadly, the ECM is composed of structural proteins (mainly collagen, 
elastin, or reticulin); glycoproteins (e.g. laminin and entactin); and proteoglycans.  The ECM serves as 
a peptide scaffold or connective tissue that cells can anchor onto.  However, it is not simply a scaf-
fold, the ECM also influences the behavior of cells at all points in life: proliferation, differentiation, 
guidance and maturation 69-71.   
The ECM can be subdivided into the interstitial matrix and the basement membrane.  The basement 
membrane is characteristically found under epithelial cells and is divided into the basal lamina and 
the lamina reticularis.  The basal lamina is in contact with epithelial cells and is organized into sheet 
like layers of ECM proteins that form a mat 40-120nm thick.  Compositionally, the basal lamina is 
mainly type IV collagen with specialized molecules on each face that help bind it to adjacent cells or 
ECM proteins.  The basal lamina is divided into three layers: lamina rara interna, lamina densa and 
lamina rara externa.  The lamina rara interna and externa are very similar; both contain the glycopro-
teins laminin and entactin.  The lamina densa is 30–70nm thick, contains type IV collagen and is eas-
ily seen using electron microscopy because it is electron dense.  Finally, the basement membrane is 
not complete without the underlying lamina reticularis, which is produced by fibroblast in connective 
tissue and is made of type VII collagen (fibrillary collagen) that tether it to the underlying connective 
tissue (typically contains fibronectin) 72. 
The ECM influences development and migration, and plays a very important role in healing.  When 
cells are damaged and die the basal lamina remains, providing a scaffold for regenerating cells to 
migrate to the site of injury.  In some cases, as in the skin or cornea, the basal lamina becomes 
chemically altered after injury, by the addition of fibronectin, which promotes cell migration towards 
the wound 72-74. 
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1.7. Extracellular Interactions 
In any cellular niche, cell to cell and cell to extracellular matrix interactions occur through cell adhe-
sion molecules or CAMs.  Cell-cell interactions occur via the cadherin and immunoglobulin protein 
superfamilies, and selectins (in bloodstream).  Cells interact with the ECM through integrins and 
transmembrane proteoglycans.  In order to function properly, the mentioned adhesion families, except 
for the immunoglobulin superfamily and transmembrane proteoglycans, require Ca2+ or Mg2+ 72.   
Each family has a myriad of proteins with specific function(s), giving cells multiple methods to interact 
with each other and the ECM.  Although there are two families of proteins that interact with the ECM, 
we shall focus on integrins, since the interactions we are studying depend on integrins.   
1.7.1. Integrins 
The principle receptors for binding ECM molecules (i.e. – collagen, laminin, fibronectin) in animal cells 
are the integrins.  Integrins are a family of transmembrane protein receptors that bind to the ECM 
(also cell to cell adhesion in blood cells).   
Integrins function through weak bonds or low affinity interactions and are very abundant in the cell 
membrane.  When compared to other cell adhesion molecules integrins are 10 to 100 times more 
concentrated throughout the membrane.  Though many integrins bind to the ECM, they do so with 
low affinity to facilitate cell movement while allowing the cell to adhere firmly to the ECM.  If cell at-
tachment to the ECM occurred via few integrins with strong affinity the cell would be incapable of 
migrating because it would be difficult for integrins to detach from the ECM.  Therefore having many 
integrins with weak affinity for the ECM circumvents this problem.    
Integrins are more than just cell adhesion molecules, they also communicate internally with the cell.  
All integrins do not cause the same internal change, allowing cells to respond to the surrounding ECM 
depending on its composition.  One change that occurs is the re-organization of the cytoskeleton 
through the binding of actin filaments (to the β subunit) via molecules such as talin, α-actinin, and 
filamin 72, 75.  Integrins or ECM proteins can also change cellular migration 76, as demonstrated in vi-
tro, where NPCs migrated out of neurospheres faster if grown on ECM molecules than on poly-L-or-
nithine.  Furthermore, results depend on the type of ECM molecule used, as demonstrated by NPCs 
migrating faster on laminin than on fibronectin 77. 
Cells can also change their specificity for ECM molecules in accordance to an up-regulation of a spe-
cific ECM molecule.  For example, after post natal blood vessel formation and during blood vessel 
maturation in the adult CNS, brain endothelial cells switch from expressing β1 integrins that bind fi-
bronectin (α4β1 and α5β1) to express more β1 integrins that bind laminin (α1β1 and α6β1) 78.  In vitro 
studies demonstrate that fibronectin promotes brain capillary endothelial cell survival and proliferation 
79.   Therefore, integrins not only bind to the ECM but can also modify cell behavior. 
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1.1.1.1. Integrin Structure and Function 
Integrins are composed of two polypeptide subunits know as the α and β subunits.  Each subunit is a 
glycoprotein which non-covalently associates to the other to make a heterodimer.  In humans there 
are at least 18 α and 8 β subunit known 80.  Every α and β combination has yet to be identified and it 
may not be possible for all α and β subunits to form an integrin.  Currently, in humans, 24 α−β combi-
nations have been found, these can be classified into three categories β1, β2, and αv because a ma-
jority of known integrins contain these subunits.   
Across cell types the same integrin can bind to dissimilar proteins due to modifications.  Cell-type-
specific factors seem to modulate the binding activity of integrins.  Also, divalent cations (Ca2+ or 
Mg2+) are crucial for the binding of integrins to their ligands; divalent-cation-binding domains are 
found on both α and β subunit.  The integrin specificity and affinity is influenced by the bound divalent 
cation, therefore different cations allow the same integrin to bind to different ligands 72.   
One way in which ECM proteins bind to cells is through a three amino acids sequence, Arg-Gly-Asp 
(RGD) found in binding domains.  The RGD sequence is a common motif in extracellular adhesive 
proteins.  Since the RGD sequence is common, so are the proteins that bind to it, which form a family 
of homologous with affinity to RGD.  Peptides containing the RGD sequence compete for the binding 
sites on cells, so typically there are different types of adhesion proteins bound to the cells.  Cell adhe-
sion peptides can be coupled to a solid surface, causing cells to adhere to that surface.  Common 
peptides used for this purpose are laminin, collagen, entactin and fibronectin.  Even though the RGD 
sequence is competed for by receptors, each receptor recognizes its own set of adhesive proteins.  
Thus, the RGD sequence is not the only part of the adhesive proteins that is involved in receptor 
binding. 
1.7.2. Fibronectin 
The extracellular matrix contains a number of adhesive glycoproteins that bind to both cells and other 
matrix proteins.  Fibronectin is the best characterized of the extracellular matrix proteins; it is a large 
fibril-forming glycoprotein found throughout the animal kingdom.  Structurally, fibronectin is made of 
two similar but unique subunits (each almost 2500 amino acid long) which make a dimmer.  Fi-
bronectin exists, as soluble dimers, and insoluble cell-surface oligomers or fibrils seen in the 
extracellular matrix.  In the cell-surface and matrix aggregates, fibronectin dimmers are cross-linked 
to one another by disulfide bonds.  Both fibronectin subunits have folds known as globular domains 
separated by lengths of unfolded polypeptide chain.  These globular domains are the binding sites of 
specific proteins.  Fibronectin can bind to collagen, heparin and specific receptors on the surface of 
various types of cells.  The type III fibronectin repeat is among the most common of all protein binding 
domains, which binds to integrins, in vertebrates.  There are two integrins that bind to fibronectin, 
α5β1 and α3β1.  Integrin α5β1 is known to bind only to fibronectin and is suspected of being involved 
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in repair since fibronectin expression is increased around areas of injury, as seen in the CNS 81.  In 
the corpus callosum, fibronectin seems to be the principal ECM protein that astrocytes secret and that 
dorsal root ganglion cells depend on for axon growth, in vitro 82.   
1.7.3. Laminin 
Laminin is also a glycoprotein, made of three proteins chains (α, β, γ) that interact to form an asym-
metric cross heterodimer.  The three subunits α,β and γ, have 5, 3, and 3 variations, respectively.  
Thus, a total of 45 isoforms of laminin are possible.  Laminin-1 binds to collagen IV, entactin and 
heparan sulfate proteoglycan, in addition to binding to cells through integrin receptors and plasma 
membrane-associated molecules.  The known integrin receptors that laminin binds to are α1β1, α2β1, 
α3β1, α6β1, α7β1 and α6β4 83.  
The focus of this research is on NPCs, therefore let’s consider how laminin is known to affect the 
behavior of neurons.  In vivo and in vitro, laminin is required for neuronal migration 84, 85 and adhe-
sion, and neurite outgrowth 86, 87.  In development, the migratory path that neuroblasts follow contains 
laminin 88.  Furthermore, in rodents laminin is dispersed along radial glial fibers at higher concentra-
tions in the prenatal cerebellum compared with the postnatal cerebellum 89.  In the prenatal cerebel-
lum granule neurons elongate their processes along radial glial fibers suggesting that elongation is 
due to laminin found on the glial fibers.  Supporting in vitro work has shown that laminin alone is suffi-
cient to provide neurite guidance 90.  As seen much attention has been given to migration.  However, 
not much is known about the role that laminin plays in differentiation of NPCs.   
1.7.4. Laminin vs. Fibronectin 
Laminin and fibronectin differ structurally as well as functionally and the cellular responses that they 
evoke are different and sometimes opposing.  However, there is some similitude, both laminin and 
fibronectin are expressed by immature cortical astrocytes 91, 92; involved in migration 90; and ligands to 
the α3β1 integrin. 
Experiments in vitro have compared NPCs from the brains of humans and rats on different ECM pro-
teins in terms of migration, proliferation, morphology and differentiation 77.  The results show that 
laminin is better at promoting proliferation, influencing the cells to become neurons, facilitating migra-
tion and increasing the number of primary neurites extending from neurons, when compared to fi-
bronectin.  The differences in effects between fibronectin and laminin may be due to more β1 in-
tegrins binding to laminin than to fibronectin, five as apposed to two- β1 integrins, respectively.  The 
availability for more interactions may allow laminin to have greater influence in NPC behavior. 
1.8. Soluble Protein Interactions 
Besides interactions that occur through CAMs and the ECM there are also transmembrane receptors 
specific for soluble factors that promote stem cell proliferation and differentiation.  For NPCs, basic 
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fibroblast growth factor (bFGF) and epidermal growth factor (EGF) are known to maintain NPCs and 
promote their proliferation in vitro.  Additionally, Wnt has also been shown to promote proliferation 
and is important in cell cycle regulation of NPCs.   
The differentiation of NPCs into neurons, oligodendrocytes and astrocytes are also altered by soluble 
proteins which promote one of these phenotypes.  First, the differentiation of NPCs into neurons is 
apparently promoted by platelet derived growth factor (PDGF), insulin like growth factor-I (IGF-I), 
interleukin-6 (IL-6; 93) brain-derived neurotrophic factor (BDNF), retinoic acid and forskolin.  Second, 
the differentiation of NPCs into oligodendrocytes has been correlated with sonic hedge hog (SHH), 
PDGF, triiodothyronine, IGF-I and the inhibition of BMP signaling.  Finally, astrocyte differentiation 
has been shown to be promoted through the IL-6 family of cytokines (e.g. LIF), BMP, and EGF (solu-
ble factors were reviewed in 64). 
Most soluble factors are secreted by cells surrounding NPCs in vivo.  Thus, mature cells can assert 
their influence over NPCs without direct contact.  Each cell type produces its own set of factors, 
therefore each cell type should have a different affect on NPC behavior (i.e.- proliferation, differentia-
tion, migration, morphology). 
1.9. Nano-scale Topography 
In tissue engineering, the use of micron or submicron scale topography that mimics the surroundings 
of cells in vivo has been shown to elicit different cellular responses compared to planar surfaces.  
Highly ordered or random structures, such as, polymeric fibers 94, nanotubes 95, and ceramic materi-
als 96 of nanometer dimensions are being investigated for biomedical applications.  Including the 
developed of scaffolds for neural regeneration and bioelectrical interfaces 97.  Carbon nanotubes, for 
example, are being researched for their use in recording and stimulating neural tissue to restore loss 
of function in disease or injury (reviewed by Cogan et al. 95).   
Some key investigations demonstrate the applicability of nanoscale structure in neural tissue engi-
neering {reviewed - 98, 99}.  For example, twice as many NSC with elongated morphology were 
observed on 300 nm poly-L lactic acid nanofibers compared to smooth substrates 100.  That difference 
was dependent on diameter of the nanofibers but not the order or arrangement.  A cell that differenti-
ates from a NSC into an elongated morphology is typically neuronal, and not oligodendrocitic or astro-
cytic, which are highly branched or flat, respectively.  Interestingly, the differentiation of embryonic 
stem cells into astrocytes decreased on uniaxially aligned poly ( -caprolactone) nanofibers 101  and 
randomly ordered self assembled nanoscaffolds 102 compared to smooth substrates.  Furthermore, 
mature astrocytes cultured on carbon nanotubes were not as adherent compared to those on planar 
surfaces 103.  Thus, it is likely that on highly porous substrates such as nanofiber meshes or nano-
tubes arrays, a stem cell has trouble expanding into and establishing a flat astrocyte-like morphology.  
These discoveries are important for treatment of CNS injury where highly proliferative astrocytes can 
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potentially impede recovery.  Thus, any control of differentiation into astrocytes would be beneficial in 
the development of methods to reestablish neural connectivity.   
1.10. CNS Cells Interact with NPCs 
1.10.1. Astrocytes and NPCs  
Astrocytes, once thought to be merely support cells are now understood to serve vital roles 104.  Astro-
cytes in the adult brain are in direct contact with NPCs as they proliferate, migrate and differentiate 46, 
105.  Thus, astrocytes, the principle constituents in the surrounding environment of postnatal NPCs in 
the brain, contain or secrete cues that control and modify the existence of NPCs.  Astrocytes are in-
volved in routine but also critical neurogenesis where neurons must be replaced due to damage.  
When injury occurs, astrocyte activity increases, releasing growth factors and proteins that aid surviv-
ing neurons, promote neurogenesis, and affect synaptic organization 106.  
Figure 1.5.  Astrocytes from different brain regions and age co-cultured with AHPCs.  From 107 re-
printed with permission from AAAS. 
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However, astrocytes throughout the CNS are not identical and do not secrete the same growth fac-
tors or promote neurogenesis; astrocytes differ according to location, function, and age.  In a detailed 
study, astrocytes from newborn and adult rats from different areas in the brain, were co-cultured with 
NPCs 107.  In this case, NPCs were derived from the hippocampus of adult rats (aka- Adult hippocam-
pal progenitor cells (AHPCs)), and infected with a retrovirus to express GFP.  AHPCs that differenti-
ated into neurons expressed both MAP2ab (found in mature neurons) and GFP (, a), and AHPCs that 
did not differentiate into neurons only expressed GFP (green cells with no red labeling, Figure 1.5, b).  
The percentage of AHPCs that differentiated into neurons (MAP2ab IR/GFP expressing) for each 
condition was represented as a bar graph (Figure 1.5, c). 
The hippocampus was shown to contain neurogenic astrocytes in both adult and neonatal rats.  How-
ever, neonatal-hippocampal astrocytes promote neurogenesis more than adult-hippocampal astro-
cytes (, c), indicating that astrocytes in the hippocampus change as they mature.  Since the nervous 
system is still developing a short time after birth, it is fitting of neonatal astrocytes to foster neural 
development. 
If we compare astrocytes from different regions of the brain, from rats of the same age, we also find 
differences in neurogenic ability.  Astrocytes from the hippocampus were most neurogenic compared 
to astrocytes from the spinal cord (Figure 1.5, c).  These results demonstrate that astrocytes are not 
the same from different regions in the CNS and that astrocytes are integral in creating a neurogenic 
niche. 
The mechanisms by which astrocytes limit or support neurogenesis, and the dependence on the 
place and age of the mammal that astrocytes reside in, are not well-understood.  The answer possibly 
lies in the growth factors astrocytes secrete (soluble and surface adhesive), and the proteins associ-
ated to their membranes.  Both surface-based and secreted proteins were investigated and seem to 
influence the adoption of the neural cell fate 105.  The proteins that were neurogenic were Interleukins-
1β and -6 (IL-1β and IL-6) at 20 ng/mL.  A mixture of the proteins IL-1β, IL-6, VCAM-1, IP-10, cathep-
sin S and TGF-β2 caused the greatest increase on neuronal differentiation.  Yet, individually all these 
proteins except IL-1 β and IL-6 did not have an effect on AHPCs.   
There is some controversy over the influence of IL-6, which has been shown both inhibit and promote 
neuronal differentiation.  In the presence of retinoic acid, 50ng/mL of IL-6 proved to inhibit neurogene-
sis 108, 109.  Yet, IL-6 was found to be neurogenic in the absence of retinoic acid and 20 ng/mL 105.  
Yet, there are some differences between these in vitro studies that must be considered.  First, the 
areas from which NPCs were derived are different.  Therefore, the baseline differentiation profiles are 
dissimilar.  Second, the concentrations at which IL-6 was added to the media are not equal (50 ng/mL 
vs. 20 ng/mL), which possibly indicates that the influence of IL-6 is concentration dependent.  Addi-
tionally, other evidence suggests a dose depend response: microglial conditioned media (IL-6 is 
expressed by microglia), conditioned for 24h, fed to NPCs would cause cell death, but when NPCs 
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were fed media, conditioned by microglia for two hours, NPC health was not affected and the differen-
tiation prolife changed 110.  The media that had been conditioned for a longer time most likely had 
higher concentrations of proteins secreted by the microglia which seem to be detrimental to cell sur-
vival.  Third, retinoic acid combined with IL-6 maybe anti-neurogenic where as IL-6 alone is neuro-
genic.  105.  Therefore, more studies are needed to understand how IL-6 plays a role in neurogenesis.   
Figure 1.6.  Microglial response to injury in the brain111 reprinted with permission from AAAS. 
1.10.2. Activated Microglia and NPCs 
Normally, IL-1β and IL-6 are secreted by activated microglia and macrophages 112 in response to in-
jury or disease. These hormones trigger cascades that lead to the up-regulation of stress hormones 
that inhibit neurogenesis by causing inflammation (Figure 1.6).  One of the downstream hormones 
produced has been shown to induce NPCs differentiation into astrocytes 111.  Thus, one purpose of 
microglia may be to repopulate the brain of astrocytes since they are the most populous cell type in 
the brain and the most damaged when injury occurs. 
Figure 1.7.  AHPC differentiation when fed microglial conditioned media108.  Reprinted with permis-
sion from AAAS. 
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In vitro, when AHPCs were fed activated-microglia conditioned media, neurogenesis decreased, but 
not gliogenesis.  This is seen in Figure 1.7, where only the percentage of neuronal like cells (β Tubu-
lin positive cells) decreased when fed media that was conditioned by activated microglia (+) as op-
posed to media condition by non activated microglia (-); the percentage of astrocytic (GFAP positive) 
and oligodendrocitic (NG2 positive) cells did not significantly change in both conditions. 
When anti-inflammatory compounds were used, an increase in neurogenesis was shown 108.  This is 
an important discovery because patients who receive radiative therapy experienced swelling in the 
brain accompanied by cognitive impairment.  The cognitive impairment may be due to the cessation 
or decrease in neurogenesis.  Therefore, restoring neurogenesis using anti-inflammatory drugs 108 
may improve the overall life of a patient undergoing radiative therapy. 
1.10.3. Neurons and NPCs 
Figure 1.8.  Differentiation of AHPC in neuron-AHPC co-culture after six days 107, reprinted with per-
mission from AAAS 
Besides astrocytes, there are also neurons, microglia, and oligodendrocytes in the neurogenic niche 
and these cells must also play a role in differentiation.  In Figure, the percentage of differentiated 
AHPCs when co-cultured with primary astrocytes (red) or primary neurons (dark blue) is shown.  In-
terestingly, when neurons are co-cultured with AHPCs, differentiation into oligodendrocytes is aug-
mented 107 compared to mono-culture of AHPCs.  Therefore, the niche where NPCs reside is also 
influenced by factors from pre-existing neurons. 
1.11. Central Nervous System Damage 
Generally, when injury occurs in the body, the immune system’s macrophages remove damaged cells 
and debris while releasing substances that promote healing or growth.  However, the blood-spine bar-
rier slows and limits macrophage entry only to the site of trauma where the blood-spine barrier is 
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weak 113, 114.  When the spinal cord is injured, neurons and neural connections are destroyed and de-
bris is created.  Many glycoproteins found in the debris inhibit axonal growth 115, 116.  Since the im-
mune system’s intervention is slow and restricted in the CNS (compared to the peripheral nervous 
system (PNS)), the injury is not properly “cleaned” and healing substances are not delivered.  Fur-
thermore, astrocyte proliferation is activated 106 producing a physical and chemical (astrocyte secrete 
soluble factors) barrier, known as the “glial scar”, through which surviving neurons cannot extend their 
axons 117.  Simply stated, an inhospitable environment which prevents axonal growth 118, 119 emerges 
and remains after CNS injury. 
1.11.1. CNS Repair Strategies 
Since the PNS can regenerate when damaged, early attempts to repair the CNS involved PNS tissue 
transplants 120.  In 1980, PNS tissue grafted into damaged regions of the brain and spinal cord pro-
moted axonal re-growth of CNS axons 121, 122.  Grafts composed of similar tissues, such as fetal spinal 
cord tissue 123, also showed beneficial results.  Further research made nerve grafts the main ap-
proach when repairing transections of the PNS.  However, additional surgery is necessary to remove 
donor tissue and after grafting total nerve function is not restored.  Therefore, a bioengineered solu-
tion that does not depend on donor tissue that will restore total nerve function is needed in both the 
CNS and PNS.   
Recent approaches in nerve repair investigate chemical, biological, physical and electrical stimuli to 
improve regenerative conditions.  Chemical approaches use pharmacological agents that mimic the 
action of neurotransmitters and prevent cell death or interfere with inhibitors of axonal growth 119, 124, 
125.  Biological strategies utilize cells that secrete recuperative substances or replace damaged cells 
altogether (e.g. - stem cells) 11, 62, 126.  Physical techniques employ bridges or conduits that link to-
gether a transected nerve 127, 128, and/or patterned surfaces that guide cells in the proper direction 129.  
Lastly, electrical, magnetic or electromagnetic stimulation has been applied to injured nerves in at-
tempts to stimulate axonal growth and improve recovery time 130-133. 
1.12. Electrical Stimulation 
The use of electrical stimulation as an investigative or therapeutic tool was not taken very seriously 
100 or so years ago.  Most electro-therapeutic treatments were considered quackery, providing no 
beneficial outcome.  In  is an apparatus designed to immerse a patient in an electric field (EF) or 
“negative breeze” meant to cure a broad range of ailments including male pattern baldness.  A metal 
receptor above the patient’s head and a metal plate placed beneath the patient, acted as the cathode 
and anode, respectively.  The metal plate was connected to a static-electricity generator (inside a 
wooden cabinet in Figure 1.9).  A patient might be occasional shocked due to faulty or incorrectly 
grounded wires, but no therapeutic benefit came from such a device 134. 
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Figure 1.9.  19th century “Electric Air Treatment” 134, 135. Used with permission from The American 
Physiological Society 
Such treatments were stopped by the next century, thanks to knowledge gained in human electro-
physiology.  However, the elimination of bogus treatments did not bring demise to electrotherapeutic 
treatment.  Instead, the field advanced as evidence began to show correlations between electricity 
and anatomy.  The role of electric fields (EFs) in tissues is still being investigated, but now the field of 
bioelectricity or electrical therapy is held with higher scientific regard.   
1.12.1. Physiological Endogenous Electric Fields 
The well-known action potential, one of the most significant discoveries in electrophysiology, is a 
momentary reversal in the potential difference across a plasma membrane (as in a nerve cell or mus-
cle fiber) that occurs when a cell has been activated by a stimulus.  The action potential is, in part, 
what makes neurons so unique from most other cells in the body.  However, there is another electri-
cal phenomenon discovered before the action potential, which is not usually mentioned in regular 
curriculum.  That phenomenon is known as the injury potential and occurs when a nerve or other 
tissue is damaged.  The injury potential is a voltage gradient established within the extracellular and 
intracellular space due to current flowing out of a wound. 
In intact epithelium, a uniform potential is maintained perpendicular to the plane of the epithelium.  
Due to asymmetrically distributed membrane- bound ion channels and pumps on epithelial cells, dis-
similar concentrations of ionic species are separated by the epithelium.  Na+ channels are more 
numerous at the apical side of the epithelium while K+ channels and Na+/K+-ATPase (pump) are local-
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ized at the basolateral membrane of epithelial cells.  This causes the concentration of K+ and Na+ at 
the basolateral side of the epithelium to be larger than the apical side, establishing a potential differ-
ence across the epithelium.  Thus, a concentration gradient drives ions to the apical side were 
possible, such as between the cells.  Gap junctions unite epithelial cells creating a resistance to the 
flow of ionic species from the basolateral to the apical side of the epithelium 136. 
When a break occurs across multiple cell layers, as occurs in injury, a low resistance pathway is cre-
ated for ionic current flow between the basolateral and apical sides of the epithelium.  Therefore, a 
potential gradient (or EF) with a positive vector pointing toward the wound is created.  The EF that 
arises due to a wound is found in the subepithelium or at the basolateral side of the epithelium and 
runs parallel to the plane of the epithelium.  The EF or injury potential guides wound healing by mak-
ing cells migrate in the direction of the wound.  Furthermore, the rate of mitosis increases, the mitotic 
spindle aligns perpendicularly to the EF and neurite outgrowth is directed in the direction of the EF 
vector 136.   
For most cell types that respond to EFs or the injury potential, there seems to be a minimum EF 
strength that will elicit a cellular response and an EF strength that maximizes the response.  In the 
case of the human corneal endothelial cells, alignment of their mitotic spindles perpendicularly to the 
vector of a DC EF is most prominent at 200mV/mm 137.  There are two recent, illustrated, thorough 
and well written articles about the injury potential related to wound healing and the history of the injury 
potential 135, 136. 
1.12.2. Electrical Stimulation of the Nervous System 
Electrical stimulus has been applied therapeutically to improve the regeneration of nerve cells in the 
nervous system.  The type of EFs used can be direct (DC), alternating current (AC), and electromag-
netic.  The sciatic nerve of rats is a common model used to study the regeneration of the PNS.  The 
two types of trauma commonly studied are crush lesions and transections.  After the animal is injured 
the electrical stimulation is applied and the results are evaluated. 
1.12.3. Constant Electric Fields In Vivo 
The use of constant EFs to treat nervous system injury is effective at stimulating re-growth of axons 
as long as the cathode is present distally, otherwise no benefits are observed 138.  When an EF is 
created in air, electrons flows form the anode to the cathode.  However, when an EF applied is ap-
plied through tissue or culture media, ions carry the charge from the anode to the cathode.  The 
movement of ions from anode to cathode is the reason that constant EFs are generally effective only 
when the cathode is place past the injury in the direction of desired growth.  Conversely, if the cath-
ode is placed proximally to the injury, the EF vector will be against the direction of desired growth, 
which seems to hinder regeneration 139.   
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Constant EFs show similar types of improvements in the regeneration of nerves.  For example, elec-
trodes placed intraluminally in transected rat sciatic nerves were used to apply a weak-DC EF.  After 
treatment,  the regenerated-axonal distance in the rats sciatic nerve was 69% longer than that of 
untreated rats 132.  However, the age of the treated rat has an effect on the improved rate of recovery 
due to constant EF treatment.  A constant EF in 10-month old rats showed an increase in recovery 
rate (measured by a behavioral test) of 21% compared to controls 140.  However, younger rats (3 
months) did not have significant improvement in recovery.  The unaltered recovery rate in younger 
rates is thought to be due to younger rats having a better healing ability than older rats: two- to three-
month rats heal 24% faster than 9 to 10 month old rats 141.   
1.12.4. Electromagnetic Stimulation In Vivo 
P. Jagadeesh and D. Wilson 142 were one of the first to explore the effects of electromagnetic fields 
on nerve regeneration by stimulating the median-ulnar nerves with a radio frequency signal (5-
120mV/cm2) 142.  Transected median-ulnar nerves were stimulated for 15 minutes each day for up to 
60 days.  From observations seen thirty days from the start of treatment, the animals treated with the 
pulsed electromagnetic field (PEMF) showed significant restoration of nerve conduction activity and 
larger diameter nerve fibers as compared to untreated rats 142.  Similarly, rats with transected sciatic 
nerves were completely subjected to PEMF.  Treated rats regained motor function in four weeks in-
stead of untreated rats, which regained motor function in eight weeks 143.  Additionally, sinusoidal 
electromagnetic fields were applied to a crushed sciatic nerve model with similar results.  However, 
regeneration was attributed to earlier stages in re-growth of the transected nerve 132. 
1.12.5. Therapeutic Electrical Stimulation in the CNS 
Jagadeesh and Wilson extended their studies of electrical stimulation from the PNS to the CNS using 
cats.  Cats were treated with PEMF stimulation after transversely cutting half-way into the spinal cord 
(hemicordotomy).  The PEMF treatment consisted of 50mW/cm2 at 400 pulses/second applied 30 
minutes each day for one month.  After three months, the spinal cord was dissected, sectioned and 
histologically analyzed.  In treated cats, extent of scarring was reduced and neurons traversed the 
region of the hemicordotomy 142.  Therefore, electrical stimulation has shown potential in achieving 
axonal growth across the glial scar, which is one of the greatest challenges in spinal cord repair. 
More recent use of electrical stimulation to repair spinal cord injury (SCI) has also been researched in 
guinea pigs and dogs.  The research of Borgens et. al. in guinea pigs, first demonstrated that axons 
could grow into the glial scar and in some cases around the glial scar 144, 145.  However, axons were 
not shown to grow through the glial scar.  Despite this, functional recovery occurred in guinea pigs 
with SCI treated with a 200μV/mm voltage gradient was demonstrated 146.  Behavioral recovery was 
studied using the cutaneous trunci muscle reflex, a useful reflex when studying SCI recovery 147.  This 
led to trials in dogs 148 using implantable electrical stimulators.  The trials in dogs used an oscillating 
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electrical field switching polarity every 15 min as opposed to the previous studies in guinea pigs 
where the field did not oscillate.  The use of an oscillating EF on dogs with SCI showed improvement 
in every category of functional evaluation at 6-weeks and 6-months, with no reverse trend.  The 
stimulators used in dogs were designed for future use in human clinical trials in humans.  Recently, 
human phase 1 clinical trials of SCI with the oscillating field stimulation were shown to be safe and 
neurologically beneficial to patients.  No severe adverse effects were observed after 1 year of treat-
ment in 10 patients and there was an improvement in somatosensory tests 133.  These trials are 
evidence that electrical stimulation may achieve significant therapeutic use.  Yet, these EF treatments 
seem to be beneficial only if applied during the initial recovery period post SCI.   
Other studies, that use electrical stimulation in combination with locomotive training to treat chronic 
SCI, have shown to help rehabilitate walking 149.  In either case, electrical stimulation was shown to 
have a promising future in the regeneration of the spinal cord and possibly the entire nervous system. 
1.12.6. Extracellular Electrical Stimulation In Vitro 
When undertaking extracellular stimulation, one encounters the complexity of merging three fields of 
study into one; electrical engineering, electrochemistry and cellular biology.  In engineering a system 
to stimulate cells in vitro knowledge must be used.  The electrical stimulation apparatuses and the 
characteristics of the stimuli that may be applied gives researchers a myriad of conditions or stimuli to 
choose from.  This can be frustrating when determining the appropriate variable combination that will 
produce a desired result.  The probability of discerning those values can require many repetitions and 
thorough statistical analysis.  Since experiments are done on live cells/tissue, one must consider 
possible electrochemical reactions that occur when placing electrodes in cell culture media/tissue.  
Electrode material must be chosen wisely so that the vitality of the cells is not affected or the elec-
trodes are not rendered useless.  Most cells are sensitive to minute changes in the media and thus 
any change in the media will usually negatively affect the cells.  Finally, the assays used to determine 
the effect of electrical/electromagnetic/magnetic stimulation have to be carefully thought of and incor-
porated into the design.  For example, if immunocytochemistry is used as an assay, multiple sets of 
statistically significant cell populations need to be electrically stimulated.  So, when designing such an 
apparatus, many stipulations must be considered. 
1.12.7. Stimulation Methodology 
First, there are many ways to stimulate cells with a form of electricity.  One thing that most devices 
have in common is the way in which stimulation is applied to the cells.  Usually an EF is created 
around growing or proliferating cells.  Ironically, this is essentially a scaled down version of the elec-
tric air bath that served no therapeutic purpose (Figure 1.9).  EFs can be applied in two fashions, with 
electrodes submerged in the media and electrodes that surround the chamber where the cell are 
grown.  In the first case an electric current can be delivered to the cells with micro-wires placed 
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around or on the cells 150, semiconductor-based multi-electrode arrays 151-158, electrically conducting 
polymers 159, 160, agar saline bridges 161, or graphite rods 162.   
Furthermore, cells can be grown on a surface that is electrically conductive and serves as one of the 
electrodes (working electrode).  For this, most groups use a potentiostat: an instrument that holds a 
constant voltage, across the growth media, by varying the current in response to changes in resis-
tance.  Two electrodes are placed in the media, one is for the potentiostat to measure the voltage 
change (reference electrode) and the other is to deliver the electrical stimulus (counter electrode) to 
the cells via the media.  The counter electrode acting as the opposing terminal that completes the 
circuit with the electrically conductive surface or reference electrode 163.  Of course, the working elec-
trode must allow the cells to grow without any abnormality.   
Others have stimulated cells without electrode to media contact, reducing changes in pH, chances for 
contamination, and electrode by-products from electrochemical reactions.  The caveat being that 
more power is needed to supply the same dose compared to electrodes placed directly in the growth 
media where the cells are maintained.  One of the simplest ways to achieve this is to use parallel 
metal plates (i.e.-stainless steal) to create a capacitive EF that surrounds petri dishes 164.  Similarly, 
electromagnetic stimulation through a large solenoid 165 or with other arrangements 166-170, and mag-
netic fields 171-173 have been used. 
1.12.8. Signal Selection 
Second, the electrical signal that is chosen for stimulation has many variables.  The stimulus can be 
direct current (DC - constant voltage) 174, 175, alternating current 174, 176, biphasic, or monophasic 
(pulses with only either positive or negative components) 177, 178.  Furthermore, the signal can be 
modified in terms of frequency, amplitude, impulse duration, impulse delay and waveform.  Typical 
waveforms used are square or rectangular 177-179, triangular and sinusoidal 155, 180.  Most function gen-
erators now allow unique waveform to be created so the signal possibilities are endless.   
1.12.9. Electrode Material 
When considering the material to be used as electrodes, one must consider cost, reusability, reversi-
bility, and how the material may affect the cells.  Some common electrode materials used in 
electrophysiology are Ag/AgCl, Pt, Au and graphite.  These electrodes are used to establish an EF 
directly in the media, converting the flow of electrons into the flow of ions and vice versa, allowing 
current to be passed in a consistent manner. 
Ag/AgCl electrodes are economic and reversible, yet they are exhaustible and brittle.  They can also 
become imbalanced when using two half-cells to drive create an EF.  In other words, differences in 
the concentration of AgCl can build up on the electrodes (Figure 1.10).  This decreases or increases 
the amount of current that is being applied (depending on direction of applied current) from one elec-
trode to the other.  Electrodes pairs can be equilibrated by connecting and placing them in same 
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saline solution.  To increase the lifetime of the electrodes, when using a constant current or EF, elec-
trodes should be alternated as cathode and anode, so that the AgCl that is removed (at the negative 
pole) can then be regenerated (at the positive pole) and vice versa.  In other words the amount of 
current and time that passes through the electrode as a cathode should be approximately the same 
when using that same electrode as an anode to limit electrode exhaustion and keep electrodes bal-
anced. 
Figure 1.10.  Electrochemical Reactions of Ag/AgCl and Pt in Aqueous Solution modified from 181 
Graphite electrodes are not easily exhaustible and do not accumulate ionic species.  Graphite is a 
good electrode material because of high electrical conductivity; acceptable corrosion resistance; high 
purity; inertness with ionic species; low cost; and ease of fabrication into composite structures.  How-
ever, graphite is brittle and will easily crumble when handled. 
Platinum is inexhaustible and does not accumulate ionic species, but is expensive.  Some studies 
indicate that Pt dissolution occurs and electrochemical byproducts are produced when Pt is used as 
an electrode 182, 183, but this was ameliorated when proteins were added to the media 183.  Also, the 
pH of the media can change due to electrolysis of water (H2 and O2 gas release).  To minimize elec-
trolysis low currents should be used (1mA was suggested by 184).  Yet, compared to other electrode 
materials Pt is a good choice. 
1.12.10. Changes in Hydrogen Concentration 
With the complexity of choosing a signal, it is logical to attempt a constant EF signal that eliminates 
variables (e.g. – frequency, waveform, etc) and allows any effect to be correlated with the strength 
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and time of stimulation.  The caveat is that the pH of the media will be changed when using a con-
stant current, so one must design a system that prevents cells from experiencing change in pH to use 
DC.  Solving this problem can often be difficult.  Most often media perfusion is a good solution, but 
this increases the risk of contamination. 
One other solution is the use of agar salt bridges to prevent byproducts and changes in pH caused by 
the electrodes to enter the media.  However, the saline in the salt bridges will diffuse out and media 
will diffuse into the salt bridge when stimulating cells for an extended period and temperatures close 
to the agar gelation temperature.  The concentration difference between the media and agar-saline 
bridge drives the diffusion of salt into the media and of media into the salt bridge.  Diffusion will be 
slower at room temperature than at incubator temperature which is 37°C.  At temperatures close to 
37°C agar is close or at its gelation temperature allowing diffusion in and out of the agar.  Additionally, 
agar has been shown to cause changes in the genetic material of cells when an electromagnetic field 
is applied this may not be related to DC stimulation but should be taken as a precaution 185.  There-
fore, using agar salt bridges is an appropriate solution for experiments on cold blooded animal cells, 
but for mammalian cells media perfusion may be better.   
1.12.11. Cellular Response to Electric Fields In Vitro 
The effect of any electrical stimulation is not predictable or the same for all cell types.  There is no 
individual signal that results in the same cellular response in all cell types.  Albeit a strong electric 
signal that passes high enough current through the cell to cause cell death.  A thorough review, writ-
ten by Nuccitelli et. al, where the effects of in vitro electrical stimulation on several cells types are 
listed 136, shows that no single response to an identical stimulus is the same for all cell types.  The 
cells mentioned by Nuccitelli et. al. were stimulated with DC EFs.  Cells types that have been stimu-
lated with other methodologies are: PC12 cells 159, 163, astroglial cells 186, HeLa cancer cells 187, and 
epithelial cells161, again, with no identical response to a particular stimulus. 
The focus of this chapter is on electrical stimulation related to the nervous system; therefore studies 
with PC12 and astroglial cells are considered here in greater detail.  PC12 cells were stimulated with 
rectangular impulses of 200mV and 400mV, peak-to-peak, with frequencies of 50Hz, 100Hz, 500Hz 
and 1 kHz for 96h.  The result was that PC12 cells matured and extended neurites without the use of 
NGF.  In other words electrical stimulation caused the cells to differentiate into more mature neurons, 
which normally only occurs by incorporating NGF into the media 163. 
In the latter study, astroglial cells were shown to secrete NGF when an electrical stimulation was 
applied  186.  A 10Hz, sine wave with a potential difference of +0.3V was shown to maximize the 
amount of NGF secreted into the media.  These two studies are related since they both show that 
electrical stimulation affects the dependency on or the quantity of secreted NGF.  These relationships 
help determine the mechanisms or pathways through which electrical stimulation alters cell behavior. 
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1.13. Neurons in Electric Fields 
Despite the different cell types investigated using electrical stimulation; neurons are probably the 
most thoroughly researched in this context, with myocardial cells following the lead.  The relationship 
between neurons and EFs has been investigated mostly using neurons derived from cold blooded 
animal, which eliminates the need for equipment such as temperature and CO2 controlled incubators. 
The work of McCaig et. al. on spinal cord neurons from embryonic frogs (Xenopus laevis) using an 
agar bridge setup 135 is a great example.  McCaig et. al., investigated the effects of EFs on axon 
guidance or turning, axonal growth rate, growth cone receptors, secondary messengers and cy-
toskeletal proteins.   
1.13.1. Axon Guidance 
Galvanotropism occurs at different thresholds for different cells types 136.  The same can be said 
about the different types of neurons and the strength of the EF needed to initiation neurites turning.  
Threshold as low as 7mV/mm have been reported to initiate neurite grow cone turning 136.  If neurite 
turning were dependent only on EF strength, then determining an underlying mechanism would not 
be such a daunting task.   
Surface adhesion molecules or extracellular matrix components affect the influence an EF has on 
cells 188.  Neurons examined by Rajnicek et. al. turned cathodally in the presence of an EF on culture 
plastic (control).  Neurites on laminin or on PLL with laminin remained cathodal, although not as 
prominent as on culture plastic.  However, on PLL, neurite growth under an EF changed direction 
(compared to control) toward the anode 188.  PLL is strongly cationic, these experiments demon-
strated that surface charge affected neurite guidance, but does not cause a complete change in 
growth in an EF.   
A misconception can be that neurites turn towards the cathode, because the overwhelming majority 
of experiments were carried out using embryonic Xenopus neurons to demonstrate neurites are di-
rected towards the cathode in an EF 189 (Figure 1.11).  For motor neurons from cold blooded animals 
like the Xenopus, cathodal turning is usually true 190.  However, neurite turning varies for other neu-
ronal cell types and species.  For example, processes from sensory neurons did not turn at all 191, 
neurites from mammalian PC12 cells (adrenal tumor cells that produce cells with neuronal properties) 
turned towards the anode 192, and rat hippocampal neurons aligned their process perpendicularly to 
the EF vector 193. 
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Figure 1.11.  Cathodal turning of axons from embryonic Xenopus spinal cord neurons, modified from 
135.  Used with permission of The American Physiological Society 
Thus, the influence an EF may have on neurites was dependent on EF strength, time of exposure, 
neuronal cell type and species, the ECM proteins used or the charge on the substratum (on which the 
cells are cultured), and if the neuronal projection is axonal or dendritic (for axonal turning) 135.  These 
variables create a complicated “puzzle to piece together” when determining the cellular mechanics 
that produce responses to EFs. 
1.13.2. Cellular Level Changes in EFs 
It has been proposed that neural growth cone guidance or galvanotaxis in an EF is due to an accu-
mulation or concentration of receptor and voltage gated channels in the membrane facing the 
direction of movement or turning (Figure 1.12, A).  The receptors and channels involved are similar to 
those involved in chemotropic guidance.  For example, in neurons, poly-saccharide-binging plant 
lectins receptors, such as, concanavalin A receptor 194 and acetylcholine receptors (AChRs) 195, 196 
were asymmetrically distributed in an EF.  Similarly, in corneal epithelial cells and fibroblasts, epider-
mal growth factor rector (EGFR) became unequally distributed in an EF 135.  These receptors were 
shown to accumulate on areas of the cell membrane facing the cathode. 
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Figure 1.12.  Growth cone changes due to an EF 135.  Used with permission from The American 
Physiological Society 
Since more than one type of AChR exists, the dependency of neurite guidance on nicotinic and mus-
carinic AChR in an EF was tested.  When nicotinic AChRs were blocked with D-tubocurare cathodal 
turning did not occur, but when muscarinic AChRs were blocked with the antagonist atropine and/or 
suramin, cathodal turning was enhanced 197.  Atropine and suramin are also P2-purinoceptor and 
bFGF receptor antagonists.  Therefore, the interaction of P2-purinoceptors and bFGF receptors with 
an EF cannot be ruled out. 
The release of ACh can be enhanced using neurotrophin 3 (NT-3) and BDNF as demonstrated in 
embryonic Xenopus neuromuscular synapses.  The addition of either NT-3 or BDNF to the media of 
cells grown in an EF, enhanced growth cone attraction 3-fold at 150mV/mm and also reduced the 
threshold required for cathodal guidance.  This effect was shown to be dependent on trkB and trkC 
(both bind NT-3, but trkC binds with greater affinity) receptors by blocking NT-3-trk receptor interac-
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tion using antagonist K252a.  Not all growth factors tested enhanced growth cone turning. For exam-
ple, nerve growth factor (NGF) and ciliary neurotorphic factor (CNTF) had no affect on growth cone 
guidance 198. 
These results implicate three receptors in the regulation of EF induced growth cone turning or neurite 
guidance: P2-purinoceptor, bFGF receptor and AChR.  Therefore, there does not seem to be a single 
receptor responsible for galvanotaxis or growth cone guidance by an EF.  Instead, combinations of 
signals/receptors dictate whether cells are guided by an EF.   
1.13.3. Asymmetric Accumulation of Membrane Bound Proteins 
As demonstrated, some receptors accumulate at the cathode facing side of the cell membrane, in an 
EF.  Proteins can be forced to migrate in an EF due to the charge of the protein and the charge on 
the cell membrane.  Typically membrane bound proteins (i.e. – integrins, neurotrophic receptors) are 
negatively charged and so is the cell membrane.  In the presence of an electric field, membrane 
bound proteins are acted on by:  (1) electrophoretic force, as observed in Western Blot (electrophore-
sis in gel) and (2) electro-osmotic fluid flow due to the movement of counter ions.  The electrophoretic 
and electro-osmotic forces are opposing in direction (for a typical negatively charged protein), attract-
ing the protein towards the anode (negative in electrolytic cell) and cathode, respectively.  The 
balance of these counteracting forces dictates the direction in which membrane bound proteins move.  
The magnitude of these forces depends on the surface charge of the protein; the relative viscosity of 
the membrane, to that of the aqueous phase; and the size of the membrane bound protein, the ex-
tracellular portion and the portion embedded in the cell membrane. 
Surface charge can explain why sometimes negatively charged proteins don’t accumulate at one side 
of the cell in an EF.  If the zeta potential (~surface charge) for the membrane bound protein, ζ1, is 
less negative than the zeta potential for the cell surface, ζ2, the protein will be pushed by electro-
osmotic flow toward the cathode (-).  Conversely, if ζ2 is less negative than ζ1 the membrane bound 
protein will move toward the anode (+) facing side of the cell by a stronger electrophoretic force.  
Thus, if ζ1=ζ2 the protein should not move because the forces are equally balanced.  This has been 
demonstrated experimentally with the concanavalin A receptor 199. 
When receptors bind their ligands, a conformational change usually occurs, which can change how 
the receptor migrates in an EF.  Therefore, cells sometimes do not respond to an applied EF if 
ligands are bound to their receptors.  This was demonstrated using concanavalin A (Con A), which 
recognizes a commonly occurring sugar structure, α-linked mannose, found in many membrane 
bound glycoproteins.  The use of Con A prevented 88% of neurites from responding to a small EF; 
where without Con A, 75% of neurites turned towards the cathode 200.   
Receptor migration and accumulation can affect the behavior of a cell partly because of autoregula-
tion.  A good example of this is the AChR (yellow in Figure 1.12).  As mentioned previously, AChRs 
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accumulate at the cathode-facing side of the growth cone.  Also at the growth cone, acetylcholine 
(ACh; green in Figure 1.12) is spontaneously released, regulating cone growth by activating nearby 
AChR.  Since AChR accumulate on the cathode facing side of the growth cone in an EF, AChR sig-
naling cascades initiate inside the growth cone closer to the cathode promoting preferential growth 
toward the cathode (Figure 1.12, A).   
Additionally, the cell should receive or detect more signals from receptors and integrins where mem-
brane bound proteins have accumulated.  Thus, there is a greater propensity for the cell to respond to 
signals asymmetrically toward the face of the cell with the greater concentration of receptors.  As 
demonstrated by increased growth rates of neurites facing the cathode 135 and directed migration of 
epithelial cells towards the cathode 161.  
1.13.4. Calcium 
Calcium plays a very important role in mechanism of growth cone turning; substantial research by 
McCaig et al. has led to such a hypothesis (illustrated in Figure 1.12, B): “Cathodal turning requires 
influx of Ca2+ via voltage-gated Ca2+ channels (VGCC) and Ca2+ release from ryanodine and thapsi-
gargin-sensitive intracellular stores. Activation of AChRs (yellow) by spontaneous release of Ach 
(green) induces cytoplasmic Ca2+ elevation further, since the receptors are “leaky” to Ca2+.  Activation 
of the trkC and trkB receptors is also required for cathodal turning.  Addition of NT-3, the ligand for 
the trkC receptor (blue) or BDNF, the ligand for the trkB receptor (magenta) to the culture medium 
enhances the cathodal response. This implicates the AChR further because NT-3 and BDNF stimu-
late release of ACh from the growth cone, therefore enhancing the asymmetric signaling via AChRs 
at the cathodal side of the growth cone. trkB receptors and AChRs activate the phospholipase C 
(PLC), phosphatidylinositol 3-kinase (PI-3K) pathway, elevating intracellular Ca2+ even further.  Ca2+ 
elevation stimulates cAMP production via adenylate cyclase. cAMP activates the protein kinase C-
dependent kinase (PKA), which affects signaling by the rho family of small GTPases (rac1, rhoA, and 
cdc42).  Activation of rac1 and cdc42 by PKA stimulate lamellipodial and filopodial formation, respec-
tively.  This is hypothesized to underlie the EF-stimulated orientation of filopodia and lamellipodia on 
the cathode-facing sides of growth cones, which are essential for cathodal orientation. Inhibition of 
rhoA by PKA activation cathodally prevents cathodal growth cone collapse, but relatively low levels of 
PKA signaling anodally permit rho-mediated growth cone collapse, further enhancing growth cone 
asymmetry.  This leads to asymmetric tension within the growth cone and turning toward the cathode. 
(pg 963 in 135)”.  Support for this theory can be visualized using fluorescent Ca2+ labeling within 
growth cones (Figure 1.12, C and D).  When exposed to an EF of 120mV/mm the Ca2+ present in the 




   
1.14. Neural Progenitor Cells and Electric Fields 
NPCs share some characteristics with neurons; some of the same receptors and ion channels may 
be affected by an EF.  One example is the trkB signaling cascade, which is known for promoting dif-
ferentiation of NPCs 201.  Changes in these or other membrane bound proteins may influence the trkB 
cascade or other signaling cascades, causing changes in differentiation, such as, the preferential 
adoption of a specific cell fate when NPCs are exposed to an EF.  Another example is bFGF, which is 
known to control the proliferation of NPCs, and may also be involved in growth cone guidance as 
mentioned above.  Furthermore, corneal epithelial cells did not migrate or orient in EF strengths be-
low 250mV/mm unless growth factors such as EGF, bFGF and TGF-β1 were used 161.  Finally, 
calcium channels also seem to be involved in the differentiation of NPCs into neurons.  When L-type 
Ca2+  channels are blocked the rate of differentiation into neurons (TUJ1/MAP2ab IR) decreases 202.  
Speculation provides possible routes for EFs to influence NPC differentiation.  Once these routes are 
investigated, a mechanism for the differentiation of NPCs in an EF will be even more rigorous to es-
tablish than that of mature neurons, because differentiation is also complex and not well understood.   
1.15. Final Thoughts 
If the differentiation of NPCs were completely controllable and the use of electrical stimulation to treat 
CNS damage continues to improve, then cell-based and electrical-stimulatory therapies should be 
developed in the near future.  The use of electrical stimulation as a therapeutic tool is already show-
ing promising results in clinical trials by improving recovery in patients with SCI 133.  NPC based 
therapies are also being investigated, but much progress is needed in determining what extracellular 
and intracellular cues may be used to effectively control and exploit the therapeutic potential of NPC.  
Electrical stimulation is an addition cue that needs to be further investigated in the quest to control 
stem cells behavior.  The use of NPCs as a cell-based therapy has enormous potential to treat cases 
where neural cell damage is present.  Despite the complexity in understanding how electrical stimula-
tion affects CNS cells, understanding how NPCs may be used in combination with electrical 
stimulation is worthwhile.  Combing these two fields of research could produce powerful techniques 
that treat injury or disease in the CNS synergistically by aiding surviving neurons and guiding new 
neural cells that differentiate from NPCs.   
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2.1. Abstract 
To control the differentiation of neural progenitor cells (NPCs), the synergistic influence of topogra-
phy, extracellular matrix (ECM) proteins and soluble factors were investigated.  Previously, in our 
laboratory, astrocyte-derived soluble factors were found to promote differentiation of adult hippocam-
pal progenitor cells (AHPCs) into neurons when grown on a laminin substrate 93.  Here we determined 
that the ECM protein on which AHPCs are cultured does not seem to alter this neurogenic effect or 
the differentiation of AHPCs when grown alone.  However, AHPCs cultured on ECL (a combination of 
entactin, collagen and laminin) in the presence of soluble factors from hippocampal astrocytes, differ-
entiated into a significantly greater percentage of oligodendrocytes (~34% on ECL vs. ~19% on 
laminin).  Furthermore, a concomitant decrease in the percentage of proliferating cells was observed 
on the ECL (~38% on ECL vs. ~55% on laminin).  Additionally, the increase in AHPC differentiation 
into oligodendrocytes on ECL occurred only in the presence of soluble factors from astrocytes, and 
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not when AHPCs were cultured alone.  Finally, we demonstrated that microscale topography did not 
influence the phenotypic differentiation in all conditions tested.  These results show that a combina-
tion of astrocyte-derived soluble factors and ECM can dramatically affect the differentiation and 
proliferation of NPCs. 
2.2. Introduction 
The stem cell microenvironment is a complex milieu containing extracellular matrix (ECM) compo-
nents 203, chemical factors 204, cell-cell interactions 205 and distinct topography 64, 206, 207 which can 
regulate proliferation, differentiation, guidance, adhesion, and migration of stem cells 208.  The regula-
tion of stem cells occurs spatially at the microscopic level where changes in the microenvironment 
create differences in adjacent stem cells.  Determining the stimuli influencing stem cells in vivo that 
alter or control differentiation is crucial in harnessing the potential of stem cells to regenerate tissue 
with limited autonomous repair, such as the central nervous system (CNS).  Here we investigate the 
use of the aforementioned stimuli as methods to control the proliferation and differentiation of neural 
progenitor cells (NPCs) for the possible use of NPCs as a cell source for rescue and repair of the 
diseased or damaged nervous system 93.  Previous studies indicated that the differentiation of AHPCs 
cultured on poly-L-lysine (PLL) and laminin (LAM) were not influenced by micropatterning, even 
though AHPC processes aligned with the microscale topography 93, 129.  Here we determined if the 
null effect on differentiation due to microscale patterning was dependent on the ECM protein used to 
culture AHPCs.  Furthermore we explored the effect of combining micropatterning, ECM proteins and 
soluble factors from hippocampal astrocytes.  AHPCs were co-cultured with hippocampal astrocytes 
without any physical contact using a Transwell ® culture insert system (non-contact co-culture 
(NCCC)).  In NCCC, AHPCs are only influenced by astrocyte secreted factors, and ECM proteins 
were used to coat the polystyrene (PS) microscale patterned films for culturing the AHPCs.  Previ-
ously, astrocytes in NCCC with AHPCs cultured on LAM, created a neurogenic environment where 
64% of AHPCs differentiated into early neurons compared to approximately 14% when AHPCs were 
cultured alone 105.  Thus, astrocytes created a neurogenic environment in vitro, through indirect inter-
action with AHPCs via secreted soluble factors.  Besides LAM, no other ECM proteins were used in 
these previous studies 209-211, and therefore it was not determined if the neurogenic effect was de-
pendent on the ECM protein used and on potential interactions between the ECM protein and soluble 
factors.  Astrocyte-secreted soluble factors known to promote neurogenesis, such as IL-6 or IL-1β 212, 
may be dependent on NPCs growing on a specific ECM molecule.  The binding of specific integrins to 
the ECM are known to alter cellular activity in NPCs 212, and therefore changes in integrin binding 
may alter the effect of soluble factors on NPCs.  In the work presented here, the effects of different 
ECM proteins (LAM, fibronectin (FN) and ECL) on AHPCs alone or in NCCC with hippocampal astro-
cytes, with or without microscale topography, were explored.  In other words, the role that ECM 
proteins can have independently and synergistically with soluble factors and/or topography were ex-
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plored to increase our knowledge in the quest for spatial control of NPC differentiation on biomaterial 
substrates.   
2.3. Materials and Methods 
2.3.1. Astrocytes 
Astrocytes were dissected from post natal day two (PN2) rat pups as described by Recknor et. al 23.  
All procedures performed on rat pups were in accordance with and approved by the Iowa State Uni-
versity Committee on Animal Care.  Briefly, hippocampal astrocytes were obtained by dissection of 
the hippocampus followed by mechanical shear, and the enzymatic treatment with papain (20 IU/mL; 
Sigma-Aldrich Corp., St. Louis, MO).  After subsequent treatment with trypsin inhibitor solution (10 
mg/mL; Sigma), the tissue was mechanically dissociated in modified minimal essential culture me-
dium (MMEM: Invitrogen, Carlsbad, CA).  The hippocampal astrocytes were grown to confluence in 
25 cm2 tissue culture flasks (T-25; Falcon) in a culture incubator.  The culture medium, MMEM, con-
sisted of minimum essential medium (MEM; Invitrogen, Carlsbad, CA) supplemented with 40 mM 
glucose, 2 mM L-glutamine, 1 mM sodium pyruvate and 14 mM sodium bicarbonate, penicillin (100 
IU/mL) and streptomycin (100 µg/mL) with 10% v/v fetal bovine serum (FBS; HyClone, Logan, UT), 
pH 7.35.   
Enriched type-1 astrocyte cultures were prepared and maintained as previously described 212. To 
purify astrocyte cultures, less adhesive cells such as microglia and neurons were removed with rinses 
of cold culture media (5°C), and continuous stirring on a rotating table for 18 hours.  Astrocyte cul-
tures containing 95% or more immunoreactive (IR) cells for anti-GFAP, (Glial fibrillary acidic protein, 
found in astrocytes) and no IR oligodendrocytes (RIP) or neuronal cells (TUJ1) were observed (de-
termined via immunocytochemical (ICC) analysis).  No more than 5 passages were allowed for the 
astrocyte cultures. 
2.3.2. Adult Hippocampal Progenitor Cells 
Adult hippocampal progenitor cells (AHPCs) were a generous gift from Dr. F. Gage (Salk Institute for 
Biological Studies, La Jolla, CA).  The AHPCs were isolated from the dentate gyrus of the hippocam-
pus of adult Fischer 344 rats as reported by Palmer and colleagues 208, 213.  The AHPCs were 
maintained in 75 cm2 tissue culture flasks (T-75; Fisher Scientific, Pittsburgh, PA) coated with poly-L-
ornithine (10 µg/mL; Sigma) and mouse-derived laminin-1 (5 µg/mL; BD Biosciences, Bedford, MA) in 
phosphate-buffered saline (PBS; Invitrogen, Carlsbad, CA).  The AHPCs were maintained under pro-
liferation conditions by culturing in ‘’complete medium” containing Dulbecco’s modified Eagle’s 
medium/Ham’s F-12 (DMEM/F-12, 1:1; Omega Scientific, Tarzana, CA) supplemented with N2 (Gibco 
BRL, Gaithersburg, MD), 20 ng/mL basic fibroblast growth factor (human recombinant bFGF; 
Promega Corporation, Madison, WI), and 2.5 mM L-glutamine (Gibco BRL, Gaithersburg, MD).  For in 
vitro analysis, AHPCs were detached from a T-75 flask using 0.05% Trypsin-EDTA (Gibco BRL, 
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Gaithersburg, MD), harvested and collected by centrifugation at 1000g for 5 minutes.  The pellets 
were re-suspended in complete medium without bFGF (referred to as “differentiation medium”) or co-
culture medium (CCM, described below) and triturated gently.  The AHPCs were seeded initially at 
~94 cells/mm2 on micropatterned PS substrates coated with ECM proteins.  Cells were maintained at 
37°C in a 5% CO2 / 95% humidified air atmosphere for 6 days in culture medium.  Culture media was 
replenished every two days.   
2.3.3. Polystyrene Micropatterned Films 
Polystyrene (PS) films were made from a solution of PS dissolved in toluene (0.08 g/mL), and cast or 
poured over wafers that were micropatterned. The pattern was fabricated on wafers using UV lithog-
raphy and reactive ion etching as described by Recknor et al. 213. The PS solution was created by 
dissolving PS beads (MW = 125,000-250,000, Polysciences, Inc, Warrington, PA) in toluene.  After 
casting the solution, the wafer was covered with a large glass petri dish to prevent dust from settling 
on the pattern.  The toluene from this solution evaporated, leaving a film of PS that is approximately 
50-70 µm thick, with the shape of the micropattern cast onto the film.  The micropattern consisted of 
parallel ridges with height, thickness and separation of 4 μm, 14 μm and 16 μm, respectively (for 
scanning electron microscopy images and diagram, please see supplemental materials). 
2.3.4. Polystyrene Patterned Film Setup 
A reservoir was created around each PS film to minimize use of ECM proteins and AHPCs.  The res-
ervoirs were made from 22mm2 glass cover slips and 9/16 inner diameter PTFE (Teflon®) O-rings 
(Small Parts, Inc., Miami Lakes, FL) were used.  O-rings were adhered to 22 mm2, 0.15 mm thick 
glass coverslips (Fisher Scientific, Pittsburgh, PA) with Sylgard® (Dow Chemical, Midland, Michigan) 
a silicone adhesive, and allowed to dry for one day, and autoclaved the following day.  Patterned PS 
films were dipped in 70% ethanol and rinsed in sterile H20, 1 cm2 pieces were cut out using a square 
hole puncher (EK Success Ltd., Clifton, NJ), attached to the center of the O-ring with a small amount 
of Sylastic® medical adhesive (Dow Chemical, Midland, MI), and allowed to dry for a day.  The next 
day, 0.5 mL of sterile water was added to the middle of the o-ring chamber and allowed to soak for 
one day to remove residual medical adhesive solvent.  The coverslips (each with an O-ring and PS 
film adhered) were then placed in a 6-well plate and exposed to UV light for sterilization.   
2.3.5. ECM Protein Coating 
PS films were coated with poly-L-lysine (PLL, Sigma, St. Louis, MO) at 100 μg/mL prior to coating 
with laminin-1 (LAM; R & D Systems, Minneapolis, MN) or fibronectin (FN; BD Biosciences Inc, 
Franklin Lakes, NJ) at 10 μg/mL in Earle’s Balanced Salt Solution (EBSS; Invitrogen, Carlsbad, CA) 
free of divalent cations (e.g. Mg2+, Ca2+).  PS films were coated with the Entactin-Collagen-Laminin 
cell attachment matrix (ECL; Millipore, Billerica, MA) at 10 μg/mL in DMEM/F-12 but were not pre-
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coated with PLL.  Patterned PS films were submerged in PLL for one day, aspirated, rinsed with ster-
ile water, and aspirated again.  LAM, FN or ECL were incubated on the PS films for approximately 1 
to 3 days at 37°C, aspirated and rinsed with sterile water or cell culture media prior to AHPC seeding.   
2.3.6. Non-Contact Co-Culture 
In the non-contact co-cultures (NCCC), astrocytes and AHPCs were cultured in the same media, but 
not in direct contact.  Astrocytes were seeded at approximate 100 cells/mm2 on 0.4 μm pore diameter 
polyester membrane Transwell® inserts (Corning, Inc., Corning, NY) and allowed to grow for two 
days in astrocyte growth media with 10% Fetal Bovine Serum (FBS) (MMEM).  Two days later, 
AHPCs were seeded at approximately 94 cells/mm2 on 1 cm2 PS films (0.5 cm2 patterned with paral-
lel grooves) within a 9/16 inch ID O-ring, in 0.5 mL of AHPC differentiation media.  The cells were 
allowed to settle and attach to the PS film for two hours.  A combination of astrocyte growth media 
without FBS (MMEM - FBS), and AHPC differentiation media were added to the area outside the O-
rings in the 6-well petri dishes, so that when the O-rings were removed, the medias mixed and a 1:1 
ratio of AHPC-Astrocyte co-culture media (CCM) was created.  The O-rings were carefully removed, 
using sterile forceps, from each 22 mm2 #1 glass cover slips that both the PS film and O-ring were 
adhered to.  Prior to seeding AHPCs onto the PS films, the MMEM (containing FBS) in the astrocyte 
containing semipermeable Transwell® inserts, and the corresponding 6-well petri dishes was aspi-
rated; the remaining MMEM was rinsed twice with EBSS, and then replaced by CCM.  The astrocytes 
were then incubated for 4 hrs while the AHPCs were seeded and allowed to adhere to the PS films.  
Two hours after seeding the AHPCs, the Transwell® membrane inserts containing astrocytes were 
placed in the 6-well petri dishes above the AHPCs (Illustrated in Figure 2.1).  The semipermeable 
membrane inserts allow soluble factors to diffuse across the membrane.  After 6 days in vitro (DIV), 
the cultures were prepared for immunocytochemistry. 
2.3.7. Immunocytochemical Procedures 
After 6 DIV, cells were immunochemically processed.  Briefly, the media was removed with two dilu-
tions of 0.1 M PO4 buffer, then cells on the PS micropattern were fixed using 4% paraformaldehyde in 
0.1 M PO4 buffer, and rinsed in filtered PBS 7 times with 5 minutes rinses.  Cells were then incubated 
in blocking solution {5% normal donkey serum, 0.4% bovine serum albumin (BSA; Sigma), and 0.2% 
Triton X-100 (Fisher Scientific)} for 90 minutes.  Cell type specific antibody markers were used to 
identify differentiated AHPCs.  Neurons were identified using anti-class III β tubulin (TUJ1, mouse 
monoclonal IgG; R&D systems, Inc., Minneapolis, MN) and microtubule-associated protein antibody 
(MAP2ab, mouse monoclonal IgG; Sigma); oligodendrocytes, anti-RIP (mouse monoclonal IgG; De-
velopmental Studies Hybridoma Bank); and astrocytes, anti-glial fibrillary acidic protein (GFAP, 
mouse monoclonal IgG; ICN, Costa Mesa, CA) were used.  Primary antibodies, TUJ1, MAP2ab, RIP 
and GFAP were diluted with blocking solution to 1:500, 1:750, 1:1500, and 1:1000, respectively.   
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Additionally, bromodeoxyuridine (BrdU), a thymidine analogue that incorporates into DNA during the 
S phase of mitosis, was added to at least two PS substrates in each condition during the last 14hrs of 
the experiment.  The cells which had incorporated BrdU were identified with a primary antibody 
against BrdU (anti-BrdU, rat monoclonal IgG; Abcam Inc., Cambridge, MA) diluted with blocking solu-
tion 1:200. 
One phenotypic antibody was used per substrate; anti-BrdU was typically used in combination with 
the phenotypic primary antibody.  Cells on 1 cm2 PS substrates were incubated in primary antibodies 
overnight at 4°C in a humid chamber.  Then they were washed in PBS with 0.1% Triton X-100, incu-
bated in the appropriate biotinylated secondary antibodies for 1.5 hours and rinsed.  Finally cells were 
incubated in the dark for 30 minutes with streptavidin-conjugated Cy3 (Jackson ImmunoResearch, 
West Grove, PA) and 4’, 6-diamidino-2-phenylindole, dilactate (DAPI), at a dilution of 1:15,000 and 
1:1000 in PBS, respectively.  Cy3 and DAPI were used to label the primary antibodies and cell nuclei, 
respectively.  Additionally, Cy5 (Jackson ImmunoResearch, West Grove, PA) was used to indicate 
anti-BrdU immunoreactivity.  The PS patterned films containing cells were then rinsed with PBS, 7 
times for 5 minutes and mounted onto microscope slides using a mounting medium (Gel Mount; Bio-
meda Corp., Foster City, CA). 
Cells were observed using light microscopy (Nikon Diaphot-TMD bright field/phase contrast micro-
scope) during culture.  Images were captured with a charge-coupled device camera (Megaplus; 
Model 1.4; Kodak Corp., San Diego, CA) connected to a frame grabber (Megagrabber; Perceptics, 
Knoxville, TN) using NIH Image 1.58VDM software (Wayne Rasband, National Institutes of Health, 
Bethesda, MD). 
Images were taken after immunocytochemical labeling using a Nikon Eclipse (Nikon Corp.) inverted 
microscope equipped with standard epifluorescence illumination and differential interference contrast 
(DIC) optics equipped with a cooled digital camera (ORCA, Hamamatsu) controlled by MetaMorph 
software (Universal Imaging Corporation, West Chester, PA). For cells with CY5 epifluorescence, a 
Leica DM5000B (Leica Microsystems Inc., Bannockburn, IL) upright microscope equipped with a 
Retiga 1300i (QImaging Corporation, Surrey, BC, Canada) digital camera controlled by QCapture Pro 
software (QImaging Corporation, Surrey, BC, Canada) was used. 
2.3.8. Quantitative Analysis of Immunocytochemical Procedures 
Six to ten areas were analyzed on the patterned and the non-patterned side of each film.  Two to 
three images were taken for each field, corresponding to fluorescent emissions of CY3 or DAPI.  The 
third image captured was of CY5 fluorescent cells labeled with anti-BrdU.  Nuclei and immunoreactive 
(IR) cells were counted semi-automatically using Image J214. The sum of IR cells was divided by the 
sum of nuclei (DAPI-labeled) for all images per treatment to determine the percentage of immunore-
active cells for each primary antibody.  In other words, the percentage of AHPCs that differentiated 
into neurons, oligodendrocytes and astrocytes after 6 DIV and those that were proliferating 14hrs 
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before the end of the experiment, were determined for each experimental condition.  The background 
or non-specific immunoreactivity intensity was determined from cells that were exposed to secondary 
antibodies and CY3/CY5 fluorophore, but not primary antibodies (ICC controls).  Only immunoreac-
tive cells with emission intensity above the non-specific intensity threshold were counted. 
2.3.9. Image-J Semiautomatic Quantitative Analysis 
In an attempt to make cell counting automatic, a routine or macro was programmed on free imaging 
software, Image J214.  Images were processed in batches, and for each image the background fluo-
rescence was subtracted, DAPI/anti-BrdU immunoreactive nuclei were encircled, and counted 
automatically if approximately 15 to 315μm2 in area.  The procedure was semi-automatic because 
user intervention was required to include nuclei with low fluorescent intensity and/or areas not within 
the specified range (Figure 2.1).  A log of DAPI/anti-BrdU immunoreactive counts for each image was 
generated and cells that were not counted were added to create a total cell count per image.  For 
each experimental condition, all nuclei counted were summed to determine the number of cells exam-
ined.  Analogously, BrdU containing nuclei were semi-automatically counted using the macro created 
for ImageJ. 
2.3.10. Statistical Analysis 
For each antibody marker (e.g. –TUJ1, MAP2ab, RIP, GFAP and BrdU) a split-plot analysis was per-
formed.  The main plot had a randomized complete block design with a 3 x 2 factorial structure.  Day 
was treated as a random block effect.  The whole plot factors were the extracellular matrix proteins 
(LAM, FN, or ECL) and the cells in culture (AHPCs only or AHPCs in NCCC with astrocytes).  The 
split plot factor was the topography on which the AHPCs were cultured; half of the PS film had a mi-
cropatterned topography while the other half did not, providing a built-in control.  Pairwise 
comparisons among levels of a factor were made for each treatment combination of the other two 
factors. For example, AHPCs cultured alone (1 level for astrocyte-secreted components as a factor) 
on LAM, FN and ECL (3 levels of ECM factors) were compared amongst each other for the patterned 
side (1 level for topography as a factor) of the PS film.  In the previous example, there are 3 compari-
sons.  Analogously for the smooth side, there would be three more pairwise comparisons.  In total 24 
pairwise comparisons were made among the conditions (or nine when pooling data from patterned 
and smooth surfaces).  Multiple comparison adjustments for the p-values were made for these pairs 
of treatment combinations using Bonferroni’s Method.  JMP version 6.02 (Copyright © 2006 SAS 
Institute) was used to analyze the data collected for all experiments.   
2.4. Results 
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2.4.1. Differentiation 
When AHPCs were cultured alone on LAM and phenotypic data were pooled across the PS sub-
strate, 16% of the AHPCs were TUJ1-IR, 17% MAP2ab-IR, 18% RIP-IR, and 3% GFAP-IR which 
are in agreement with previous results215.  Similarly for AHPCs cultured alone on FN, 12% of the 
AHPCs were TUJ1-IR, 17% MAP2ab-IR, 14% RIP-IR, and 3% GFAP-IR; and for ECL, 22% of the 
AHPCs were TUJ1-IR, 12% MAP2ab-IR, 16% RIP-IR, and 8% GFAP-IR.  Comparisons between 
different ECM proteins, when AHPCs were cultured alone, revealed no statistically significant differ-
ences in phenotypic differentiation (Figure 2.2).  When AHPCs were cultured on LAM in NCCC with 
hippocampal astrocytes, 49% of the AHPCs were TUJ1-IR, 19% MAP2ab-IR, 19% RIP-IR, and 6% 
GFAP-IR averaging across the entire substrate.  Likewise, for AHPCs in NCCC FN, 49% of the 
AHPCs were TUJ1-IR, 20% MAP2ab-IR, 24% RIP-IR, and 6% GFAP-IR; and for NCCC ECL 43% of 
the AHPCs were TUJ1-IR, 12% MAP2ab-IR, 34% RIP-IR, and 5% GFAP-IR (Figure 2.2).  Further-
more, differences in phenotypic differentiation of AHPCs between patterned and the smooth sides of 
the PS films for each condition were not statistically significant (Figure 2.3).  
Comparing phenotypic results for AHPCs in NCCC with hippocampal astrocytes, the largest in-
creases can be observed for TUJ1-IR and RIP-IR cells.  The phenotypic differentiation into early 
neurons (TUJ1-IR) on LAM increased when AHPCs were in NCCC with hippocampal astrocytes 
compared to AHPCs alone (AHPC alone LAM: 17% versus NCCC LAM: 49%, Figure 2.2 and Figure 
2.3), which is consistent with our previous results for AHPCs on LAM in NCCC with cortical astro-
cytes216.  Yet here, the increase in early neuronal differentiation due to soluble factors from astrocytes 
observed on LAM prevailed on FN and ECL (AHPCs alone FN: 12% versus NCCC FN: 49%; AHPCs 
alone ECL: 21% versus NCCC ECL: 44%).  When comparing differentiation into the oligodendrocyte 
fate, a significant increase was induced when AHPCs were cultured on ECL in NCCC (AHPCs alone 
ECL: 16% versus NCCC ECL: 34%), yet no other ECM tested produced a significant increase in oli-
godendrocyte differentiation when AHPCs were in the NCCC condition.  However, for the astroglia 
and mature neuronal phenotypes (GFAP and MAP2ab, respectively), significant differences in differ-
entiation were not observed between AHPCs cultured alone and in NCCC conditions (Figure 2.2, and 
Figure 2.3).  These results demonstrated that the ECM protein, on which AHPCs were cultured, al-
tered the differentiation into a specific phenotype (i.e. - oligodendrocytes) in the presence of 
hippocampal-astrocyte derived soluble factors.  Surprisingly, increased oligodendrocyte differentiation 
occurred without a significant decrease in AHPC differentiation into any of the other phenotypes 
tested, and despite a majority of AHPCs differentiating into early neurons (TUJ1) in NCCC.  Thus, the 
total percentage of AHPCs that differentiated in NCCC ECL compared to other conditions was in-
creased. 
To support this result, the percent of proliferative cells during the last 16 hours of the experiment was 
assayed using BrdU (Figure 2.4, BrdU-IR).  The data gathered indicated no significant differences in 
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AHPC proliferation between the micro-patterned and smooth side of PS films for all conditions; or 
between all ECM components used to culture AHPCs alone (AHPCs alone LAM: 59%, FN: 60% and 
ECL: 63%).  However, soluble factors from hippocampal astrocytes, in synergy with ECL, significantly 
reduced the percent of proliferative cells compared to soluble factors and other ECM proteins, or 
compared to ECL alone (NCCC ECL:  38% versus NCCC LAM: ~55% or NCCC FN: 58%, or com-
pared to AHPCs alone on ECL: 63%, respectively). 
The significant differences mentioned were visually apparent before performing a quantitative analy-
sis.  NCCC conditions displayed more TUJ1-IR (leftmost column, Figure 2.5) cells compared to 
AHPCs cultured alone, where NCCC conditions had more cells with fluorescent processes axially 
aligned, reminiscent of neuronal morphology.  Stunning differences were observed in NCCC ECL 
conditions, where oligodendrocyte-like cells (RIP-IR, center column, Figure 2.5) were more numerous 
and highly branched, covering a large portion or all of the field of view.  The processes of oligoden-
drocytes and early neurons were usually found confined to the corridors or grooves of the microscale 
pattern (not quantitated).  In NCCC ECL, fewer BrdU immunoreactive nuclei (green in the rightmost 
column of Figure 2.5) were observed compared to all other conditions.  Finally, fewer cells were typi-
cally observed for AHPCs alone, cultured on FN, where the mean cells/mm2 for FN was lower than all 
other conditions (data not shown). 
2.5. Discussion 
A dramatic shift in differentiation of AHPCs toward any of the assayed phenotypes could not be at-
tributed to the use of LAM or FN, when AHPCs were cultured alone.  However, a combination of ECM 
proteins (ECL) and soluble factors from the astrocytes in NCCC conditions increased differentiation 
into oligodendrocytes significantly compared to other conditions, which indicates cellular changes are 
induced with combinations of ECM proteins not pure ECM substrates 217, 218.  This may be due to 
increased signaling received from different ECM proteins, causing a greater variety of integrin recep-
tors to interact with the substrate (e.g.- cells on ECL can interact with laminin, collagen type IV and 
entactin, not laminin only).  It is also possible that ECL interacts with soluble factors to form a com-
plex(s) 218 or may accumulate soluble factors 219 increasing substrate concentration of soluble factors 
that promote oligodendrogenesis and decreased proliferation.  The accompanying decrease in prolif-
eration (BrdU-IR) observed for AHPCs in NCCC on ECL agrees with the notion that the ECL 
substrate and astrocyte factors combined, stimulate AHPC differentiation towards oligodendrocytes 
decreasing the percentage of cells that are mitotic.  Especially since the differentiation into other cell 
types did not drastically change in NCCC on ECL, the data indicate that the decrease in proliferation 
was due to an increase in oligodendrocyte differentiation. 
ECL contains traces of growth factors that may have influenced the differentiation of AHPCs in NCCC 
toward the oligodendrocyte fate.  To determine this, individual growth factors must be tested in com-
bination with NCCC with hippocampal astrocytes.  The growth factors present in ECL are similar to 
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those found in MatrigelTM, IGF-I, PDGF, NGF, and TGF-β, and research indicates that some of these 
growth factors can increase the differentiation of NPCs into oligodendrocytes.  Specifically, PDGF is 
known to promote bipotent O2-A progenitor proliferation and differentiation into oligodendrocytes 220 
at 5 ng/mL or 10 ng/mL (for a review on factors affecting gliogenesis see Lee, et. al. 221).  Further-
more, IGF-I is known to promote the differentiation of AHPCs into oligodendroglia, at comparable 
percentages to our results, when applied at 20 - 500 ng/mL 222.  However, PDGF and IGF-I are pre-
sent at lower concentrations in MatrigelTM: 12 pg/mL and 15 ng/mL, respectively (Millipore Inc.).  
Furthermore, the ECL solution used to coat our PS substrates was diluted 1:100 from the manufac-
turer stock solution, and then aspirated after coating.  Thus, the concentrations of PDGF and IGF-I 
should have been greatly reduced once the culture well was filled with media and cells were cultured 
on the PS substrates.  It is likely that an insignificant increase in RIP-IR would be attributed to traces 
of PDGF and IGF-I found when AHPCs were cultured on ECL in NCCC with hippocampal astrocytes.  
However, this increased differentiation into oligodendrocytes was not observed when AHPCs were 
cultured alone on ECL.  Therefore, soluble factors from hippocampal astrocytes were not considered 
to magnify the effects of trace PDGF and IGF-I in NCCC ECL; instead ECL most likely altered the 
effect that soluble factors had on AHPCs, increasing the differentiation into oligodendrocytes.   
The majority of MatrigelTM is laminin, 58% (Millipore Inc.), but LAM alone did not produce the same 
effects on AHPCs in NCCC.  Therefore, to determine if the increase in RIP-IR and decrease in prolif-
eration in NCCC ECL can be attributed to a single component in ECL, collagen and entactin 
(nidogen-1) should be investigated.  Collagen for example, decreased the proliferation of Schwann 
cells, in similar research 77.  Nidogen is a ubiquitous glycoprotein that bonds non-covalently with 
laminin and collagen type IV to create a structural network/framework of the basal lamina 105.  Both, 
nidogen and collagen type-I (not collagen type IV as used here) has been shown to promote the sur-
vival and proliferation of Schwann cells 208, which are analogous to oligodendrocytes in the CNS.   
The ECL combination is closer to what NPCs may encounter in vivo since neurogenic niches are not 
composed of individual ECM components.  The possible number and type of integrin receptors that 
interact with ECL should be greater than those that interact with FN or LAM.  
Finally, the maturation of neurons, as indicated from the MAP2ab IR (Figure 2.3) was not conclusively 
influenced by the use of different ECM proteins.  The mean for each column in Figure 2.3 shows that 
FN accelerates the establishment of the neuronal phenotype when AHPCs are grown alone and in 
NCCC, compared to ECL.  However, this difference is not statistically significant.  In similar research, 
human and mouse NPCs grown on FN did not produce as many neurons (MAP2ab immunoreactive 
cells) as NPCs cultured on LAM, 6% vs. 8% (human), and 1% vs. 10% (mouse), respectively; addi-
tionally, migration and cellular process growth were slightly less proficient on FN as on LAM .  Here 
however, an increase in MAP2-IR cells was not observed when comparing any substrate.  We believe 
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that extending our experiment for longer durations would allow for NPCs to become mature neurons 
(MAP2ab immunoreactive) and allow differences between ECM substrates to become more apparent. 
Purified ECM components may not influence the differentiation profile of AHPCs grown alone or in 
NCCC, and combinations of ECM proteins may be more effective at overcoming or synergistically 
working with potent soluble growth factors.  Generally, it is possible that soluble factors have greater 
influence over cell behavior than the ECM, as is the case with bFGF which controls proliferation or IL-
6 and IL-1β which are powerful neurogenic factors secreted from astrocytes.  The data presented 
here, demonstrated that FN and LAM influenced the differentiation of AHPCs in a similar way, and 
that the ECM proteins alone were not as influential as soluble factors, from hippocampal astrocytes, 
at altering the differentiation of AHPCs (i.e. - differentiation into neurons).  
These findings can benefit the development of cell based tissue engineering strategies for nervous 
system repair.  Biodegradable conduits could be selectively coated with a combination of ECM pro-
teins such as ECL to increase the number of oligodendrocytes in select spatial locations in the 
conduits for the treatment of de-myelinating diseases like multiple sclerosis.  A successful cell based 
strategy will likely be a combination of multiple approaches: micro or nano topography to provide 
guidance to cellular processes; soluble factors released slowly by incorporating these into biodegrad-
able polymers to further promote differentiation into a desired cell type (e.g. - IGF-1 for 
oligodendroglial differentiation); and ECM proteins to further control cell fate and proliferation.  There-
fore the knowledge presented here should help understand how NPCs can be controlled and bring us 
closer to developing a cell based strategy for nerve repair. 
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Figure 2.1.  Illustration of one well in a 6 well culture plate containing an astrocyte and AHPC non-
contact co-culture.  A semipermeable membrane insert, suspends the astrocytes above AHPCs cul-
tured on 1cm2 polystyrene film (half micro-patterned).  Astrocyte-secreted molecules permeate 
through the membrane and affect AHPCs.  In “AHPC alone” conditions, AHPCs were cultured on the 
PS films without a hovering suspension of astrocytes.  SEM images of AHPCs on PS films were 
modified from Recknor et al. 2006. 
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Figure 2.2.  Florescent nuclei semi-automatically counted with a software script we developed for 
Image J to process multiple images rapidly.  Nuclei labeled with DAPI or immunocyto-chemically with 
anti-BrdU were, automatically counted and circled when they were above an automatically deter-
mined background intensity.  Nuclei (i.e.-white arrows) not counted or over-counted by the program 
were manually accounted for to corrected cell counts.   
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Figure 2.3.  Percentage of AHPCs that were immunoreactive for neuronal (TUJ1 and MAP2ab), oli-
godendroglial (RIP) and astroglial (GFAP) markers, after 6 days in vitro.  Significant differences were 
not observed between smooth and micro-patterened side of the PS films, therefore the data were 
averaged for each ECM substrate when AHPCs were cultured alone (LAM, FN, ECL) or in the pres-
ence of hippocampal astrocyte soluble factors (NCCC LAM, NCCC FN, NCCC ECL).  Significant 
contrasts were AHPCs cultured alone versus NCCC conditions, and AHPCs cultured alone versus 
NCCC ECL, where approximately 30% and 18% more AHPCs differentiated into early neurons and 
oligodendrocytes, respectively.  N (number of experiments) = 3 to 7.  For each phenotypic marker, 
conditions not connected by the same letter or character were significantly different, p<0.006.  Values 
are mean + SEM. 
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Figure 2.4.  Percentage of AHPCs that were IR with phenotypic antibodies for neurons (a; TUJ1 IR 
cells, N (number of experiment) = 4 to 7); mature neurons (b; MAP2ab IR, N= 3 to 5); oligodendro-
cytes (c; RIP-IR cells, N = 4 or 5); and astrocytes (d; GFAP-IR cells, N = 3 or 4) after 6DIV on the 
pattern and smooth sides of the PS film.  Conditions not connected by the same letter are significantly 
different, p<0.0021.  Values are mean + SEM. 
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Figure 2.5.  Percent of cells that went through the S phase of mitosis during the last 16 hours of the 
experiments as indicated by the percent of BrdU-IR cells.  Data presented are for AHPCs on the 
smooth and patterned sides of the PS films separately and pooled together.  N (number of experi-
ment) = 3 to 5.  Conditions not connected by the same letter are significantly different, p<0.0021.  
Values are mean + SEM. 
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Figure 2.6.  Epi-fluorescenct images of antibody immunoreactivity in AHPCs that had significant dif-
ferences between conditions (within each antibody).  Each column represent a different 
immunocytochemical labeled and each row represent the different condition to which the entire PS 
films were exposed.  Images here are for the patterned side of the PS films.  Alignment of cellular 
processes can be observed in TUJ1 and RIP IR cells.  The major notable differences are the increase 
in NPC differentiation of oligodendrocytes (RIP IR) and early neurons (TUJ1), in NCCC, ECL vs. all 
NCCC conditions, and all NCCC conditions vs. culture of only NPCs.  Furthermore,  fewer prolifera-
tive (BrdU containing cells) were seen for NCCC ECL conditions.  Similar results were observed for 
NPCs cultured on the non-patterned side of the PS films (not shown). All nuclei were labeled with 




   
 
Table 2.1 – Categorized details of experimental conditions or treatments. 






grown on a membrane 
insert placed in the same 
media as the AHPCs.   
 
10 µg/mL Laminin  
10 µg/mL Fibronectin 




for each protein 
AHPCs 
alone   
 
AHPCs in co-culture me-
dia 
 
10 µg/mL Laminin  
10 µg/mL Fibronectin 




for each protein 
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3.1. Abstract 
This study provides the first investigation of how highly ordered nanotube arrays can be used to con-
trol the differentiation of neural stem/progenitor cells (NSCs).  Decreased NSC differentiation into 
astrocytes was observed on highly ordered TiO2 nanotube arrays compared to planar substrates such 
as glass, while differentiation into neurons or oligodendrocytes was not altered.  Furthermore, adhe-
sion may have been slightly improved on nanotubes.  This demonstrates that it is possible to control 
NSCs differentiation through nanoporous/nanotubular structures. 
3.2. Manuscript Text 
The development of a methodology to control stem cell differentiation into specific cell types is crucial 
in implementing a cell based approach to potentially ameliorate central nervous system (CNS) dis-
eases, disorders or damage.  Cell based therapies for the CNS may eventually be based on the 
control of adult neural stem/progenitor cells (NSCs) 223-226.  Methodologies to control NSC proliferation 
and differentiation include, but are not limited to, use of soluble molecules such as leukemia inhibitory 
factor and bone derived neurotropic factor 64; extracellular matrix proteins that interact with integrin 
receptors 77, 209-211, 227; electric 228 or electromagnetic 229 fields; and substrate architecture 102, 230.  
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Nanoscale substrate architecture and topography, especially, has shown the most interesting effects 
on NSCs.  Mats of electrospun polymeric nano-fibers have demonstrated to be useful in the develop-
ing field of tissue engineering231.  For example, laminin-coated electrospun polyethersulfon fiber 
meshes increased NSC differentiation into neurons and oligodendrocytes, and that increase was 
found to be dependent on nano-fiber diameter 230.  Furthermore, processes aligned 100 and grew 
longest 100, 232 on highly ordered fibers compared to random nanofibers.   
Here we investigate another important nano-structure: nanotubes.  Previously, multilayer single 
walled carbon nanotube (SWNT) films were demonstrated to be biocompatible with embryonic NSC 
233.  However, SWNT films are not highly ordered, and therefore the “tactile” stimulus that NSCs re-
ceive is probably not equivalent for each cell.  To our knowledge we are the first to culture NSCs and 
investigate their differentiation on highly ordered nanotube arrays. The physical stimulation that NSCs 
received here is not random for each cell, and changes to NSC behavior can potentially be related to 
a measurable dimension, such as nanotube diameter.  Our aim was to determine if highly ordered 
tubular nanoscale arrays can be used to control NSCs.  
Nano-scale topography is potentially beneficial for the culture of cells due to improved adhesion and 
control of differentiation compared to smooth substrates.  Essentially, the nanotubes provide greater 
surface to area for the cells to adhere on.  Better cell adhesion leads to better integration of biomedi-
cal devices in the body.  For example bone formation around TiO2 oxide implants has been improved 
by changing the diameter of nanotubes on the surface 234.  Implants that integrate well into the bone 
are very desirable and have shown promising results even in dentistry 235.  Furthermore, increased 
healing rates have been attributed to increased differentiation into the appropriate phenotype 236 due 
to surface modified materials. TiO2 is used extensively in bone repair since it is generally known to be 
biologically inert.  Inevitably MSC contained in bone marrow come into contact with TiO2 biomedical 
implants.  Therein lies the reasoning for many investigations into the effects of nano-structure on 
MSC 96, 237, 238.  However, the response of NSCs to these surfaces had not been studied previously, 
even though MSC have the ability to differentiate into neurons and glia 239.    
Highly ordered TiO2 nanotube (60 nm) arrays were fabricated according to our previously reported 
procedure 240-242.  Briefly, Ti foil (99.7% purity, 0.25 mm thick, Sigma-Aldrich) was cut into pieces with 
dimension of 1 inch x 0.5 inch, followed by degreasing in acetone, isopropanol, and methanol se-
quentially in an ultrasonication bath. TiO2 60 nm nanotube arrays were grown on the Ti foil by 
potentialstatic electrochemical anodization in fluorine containing electrolytes. TiO2 60 nm arrays with 
pore diameter of 60 nm were formed by anodizing Ti foil in 0.5 wt% hydrofluoric acid in an ice bath 
with anodization potential of 20 V for 30 minutes.  After anodization, the Ti foil with nanotube arrays 
grown on it was immediately rinsed with large amount of DI water, followed by drying with N2 gas. The 
as-prepared TiO2 nanotube arrays were amorphous, and anatase crystalline phase was induced by 
thermal annealing at 500oC for 3 hours, which was confirmed by Raman scattering 240-242. The nanos-
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tructure of TiO2 nanotube arrays was characterized with scanning electron microscopy (SEM, JEOL 
5800 LV).   
The NSCs were a generous gift from Dr. F. Gage (Salk Institute for Biological Studies, La Jolla, CA).  
NSCs were isolated from the dentate gyrus of the hippocampus of adult Fischer 344 rats as reported 
by Palmer and colleagues 23.  They were then maintained in 75 cm2 tissue culture flasks (T-75; Fisher 
Scientific, Pittsburgh, PA) coated with poly-L-ornithine (10 µg/mL; Sigma) and mouse-derived laminin-
1 (5 µg/mL; BD Biosciences, Bedford, MA) in phosphate-buffered saline (PBS; Invitrogen, Carlsbad, 
CA).  NSCs were propagated in ‘’complete medium”, which consisted of Dulbecco’s modified Eagle’s 
medium/Ham’s F-12 (DMEM/F-12, 1:1; Omega Scientific, Tarzana, CA) supplemented with N2 (Gibco 
BRL, Gaithersburg, MD), 20 ng/mL basic fibroblast growth factor (human recombinant bFGF; 
Promega Corporation, Madison, WI), and 2.5 mM L-glutamine (Gibco BRL, Gaithersburg, MD). NSCs 
were harvested from a T-75 flask using 0.05% Trypsin-EDTA (Gibco BRL, Gaithersburg, MD) and 
collected by centrifugation at 1000g for 5 minutes.  The pellets were re-suspended and triturated gen-
tly in complete medium without bFGF and with 5% FBS.  NSCs were seeded at 100 cells/mm2 in 
35mm petri dishes (Fisher Scientific) containing one 12mm glass coverslip and a TiO2 nanotube ar-
ray.  TiO2 arrays and 12mm coverslips were cleaned with boiling RBS-35™ concentrate (Chemical 
Products R. Borghgraef S.A., Fisher Scientific) detergent (1:50 in DI water) and rinsed repeatedly in 
18MΩ water prior to cell culture.  Substrates were then coated with poly-L-lysine (100 μg/mL) and 
laminin-1 (10 μg/mL).  Culture conditions were maintained at 37°C in a 5% CO2 / 95% humidified air 
atmosphere for 6 days in culture medium.  Cell culture media was replenished every two days.   
After 6 days in vitro (DIV), the cells were immunochemically processed.  Briefly, the media was re-
moved with two dilutions of 0.1 M PO4 buffer.  Then the NSCs on 12mm glass coverslips or TiO2 
nanotube arrays were fixed using 4% paraformaldehyde in 0.1 M PO4 buffer, and rinsed in filtered 
PBS 7 times with 5 minutes rinses.  Cells were then incubated in blocking solution {5% normal don-
key serum, 0.4% bovine serum albumin (BSA; Sigma), and 0.2% Triton X-100 (Fisher Scientific)} for 
120 minutes.  Cell type specific antibody markers were used to identify differentiated NSCs.  Early 
neurons were identified using anti-class III β tubulin (TUJ1, mouse monoclonal IgG; R&D systems, 
Inc., Minneapolis, MN); oligodendrocytes were identified using anti-RIP (mouse monoclonal IgG; De-
velopmental Studies Hybridoma Bank); and astrocytes using anti-glial fibrillary acidic protein (GFAP, 
mouse monoclonal IgG; ICN, Costa Mesa, CA) were used.  Primary antibodies, TUJ1, RIP and GFAP 
were diluted with blocking solution at 1:500, 1:1500, and 1:600, respectively.   
One phenotypic antibody was used per substrate.  Cells were incubated in primary antibodies over-
night at 4°C in a humid chamber and repeatedly rinsed in PBS.  Next, cells were incubated in the 
appropriate biotinylated secondary antibodies and 4’, 6-diamidino-2-phenylindole, dilactate (DAPI), at 
1:60 in blocking solution for 90 minutes and rinsed.  Finally, cells were incubated in the dark with 
streptavidin-conjugated Cy3 (Jackson ImmunoResearch, West Grove, PA) for 30 minutes, at 
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1:15,000 in PBS.  The substrates were then rinsed repeatedly with PBS and mounted onto micro-
scope slides using a mounting medium (Gel Mount; Biomeda Corp., Foster City, CA). 
To observe and photograph immunocytochemical labeling, a Nikon TE2000 (Nikon Corp., Melville, 
NY) inverted microscope equipped with standard epifluorescence illumination and equipped with a 
cooled digital camera (Cascade® 512B or Coolsnap® EZ; Photometrics, Tucson, AZ) controlled by 
MetaMorph software (Universal Imaging Corporation, West Chester, PA) was used.  
Ten to twelve areas were imaged under fluorescent illumination.  Two images were taken for each 
field analyzed, corresponding to fluorescent emissions of DAPI and CY3, and superimposed (Figure 
3.2).  Nuclei and immunoreactive (IR) cells were counted semi-automatically using Image J 214 (see 
supporting information).  The percentage of NSCs that differentiated into neurons, oligodendrocytes 
and astrocytes after 6 DIV, were determined for each experimental condition.  The background or 
non-specific immunoreactive intensity was determined from cells that were exposed to secondary 
antibodies and CY3 fluorophore, but not to primary antibodies (ICC controls).  Only immunoreactive 
cells with emission intensities above the non-specific intensity threshold were considered positively 
labeled.  ANOVA was performed on data of antibody marker counts (e.g. – TUJ1, RIP, and GFAP) 
using JMP version 8.0.1 (Copyright © 2006 SAS Institute) to statistically analyze the data collected for 
all experiments.   
After 6 day of culture, the density of neural progenitor cells seemed greater on the nanotubes as indi-
cated by DAPI staining (Figure 3.2).  Cell counts of fluorescent micrographs images were used to 
quantify the cell density after immunocytochemical procedures ( 
Figure 3.3). The mean values indicated fewer cells on the glass coverslips than on the nanotubes 
(163 ± 42 vs. 219 ± 42, p = 0.19). However, statistical analysis indicated no difference between the 
NSCs density on 60 nm nanotubes arrays compared to glass coverslips.   
The percentage of NSCs that differentiated into each of the three neural phenotypes (Figure 3.2 and  
Figure 3.4) was determined.  Out of four experiments, the least squared mean percentage of TUJ1 
immunoreactive NSCs on glass and 60 nm TiO2 nanotubes was found to be 41.1 ± 4.7% and 35.9 ± 
4.4%.  Similarly for RIP immunoreactive cells, the percentage of RIP positive cells for the control and 
60 nm TiO2 nanotubes was 36.3 ± 6.7% and 29.7 ± 5.2%, respectively.  The least mean square per-
centage of TUJ1 and RIP immunoreactive cells were statistically consistent over the three conditions.  
Most importantly, the percentages of GFAP immunoreactive cells in the control and 60 nm TiO2 nano-
tubes were 16.5 ± 2.6% and 6.7 ± 2.5%.  Thus, there were significantly fewer GFAP positive cells on 
the 60 nm TiO2 compared to glass (n = 4, p < 0.034).    
The only other investigation of growth and differentiation of NSC on nanotubes by Jan and Kotov 233 
is very different from our study.  In our study, the nanotubes here were highly ordered and aligned 
vertically in an array, as opposed to being randomly dispersed in a film 233. Second, NSCs here were 
derived from an adult rat, and not an embryonic mouse.  Third, TiO2 and not carbon was used to cre-
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ate the nanotubes.  We demonstrate a decrease in the differentiation into astrocytes (GFAP+) without 
changes to the differentiation into neurons or oligodendrocytes (TUJ1+ and RIP+, respectively) on 
highly ordered TiO2 nanotube arrays.  In contrast, embryonic NSCs differentiated mostly into astro-
cyte-like cells (~50%) and their differentiation was not altered by carbon SWNT 233.  At the site of 
spinal cord injury, where active gliosis leads to the glial scar 243-245, it would not be desirable for trans-
planted NSCs to differentiate into astrocytes.  Instead the reestablishment of neuronal connections 
and remyelination of those connections by new neurons and oligodendrocytes, respectively, is nec-
essary.  Thus, modifying the surface of grafts with highly ordered nano-porous topography using TiO2 
nanotube arrays may increase the regeneration efficacy of transplanted NSCs.  The nano-topography 
would minimize NSC differentiation into astrocytes, while maintaining the differentiation of NSC into 
neurons and oligodendrocytes. 
Also, a possible method of drug delivery via nanotubes has been demonstrated chemically 246.  
Therefore, besides the topographical influence that nanotubes provide, pharmacological agents or 
growth factors could also be released at a specific time to induce differentiation before or after trans-
plantation.  For example insulin-like growth factor-1 could be used and released to cause 
differentiation into oligodendrocytes.  Similarly, “nano-patterned” surfaces may eventually be tailored 
with polymer coatings 247 to further biologically interact with its surroundings.   
We have previously investigated the use of microscale substrate architecture to control NSC 129, 248.  
The major advantage of nanoscale over microscale is that it tends to be more biologically interactive 
altering growth, survival, and differentiation 249.  Hence, some nanoscale architecture is considered 
more biologically active and more capable of integrating with cellular function.  Use of free nanoscale 
particles or nanotubes however, may negatively affect cell health and viability.  Free titanium dioxide 
nanoparticles have been demonstrated to be cytotoxic to human neural crest cells and fibroblasts 250.  
Furthermore, nanowires and nanotubes can become incorporated into the cytoplasm and cause cyto-
toxic effects 251.  In the lungs, TiO2 nanofibers and other ultrafine-TiO2 particles produced pulmonary 
fibrosis regardless of particle size 252, 253.  Therefore, the use of nanotube arrays as opposed to free 
nanotubes circumvents these potential issues. 
Studies of NSCs on electrospun nanofibers have shown that NSCs differentiate preferentially into 
neurons or oligodendrocytes.  However, they do not demonstrate a decrease in GFAP expression as 
presented here for NSCs on nanotubes.  This is important for therapeutic applications because pre-
vention of the “glial scar” would allow neurons to reestablish connections after spinal cord injury.  This 
may lead to applications were the glial scar is prevented or ameliorated through the use of a nano-
porous material to treat of spinal chord injury.  The size of the TiO2 nanotube in the arrays can be 
potentially controlled 240-242 to investigate the effect of nanotube diameter on NSC differentiation. With 
progress, a highly ordered nanoporous topography may improve the propagation of NSC colonies 
used in transplants, or induce NSC differentiation into specific phenotypes in transplanted tissues.   
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3.4. Supporting Information Paragraph  
Semi-automatic Image Analysis- In an attempt to make cell counting automatic, a routine or macro 
was programmed on free imaging software, Image J 214.  Images were processed in batches, and for 
each image, the background fluorescence was subtracted.  DAPI immunoreactive nuclei that were 
approximately 15 to 315 μm2 were encircled, and counted automatically.  The procedure was semi-
automatic, as user intervention was required to determine the total cell count by manually counting 
nuclei with low fluorescent intensity, clumped nuclei, and/or areas out of the specified range.  For 
each experimental condition, all nuclei counted were summed to determine the number of cells exam-
ined.  The total DAPI stained nuclei divided by the total actual area photographed yielded the cell 
density (cells per mm2) for each treatment. 
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Figure 3.1.  Scanning electron microscopy (SEM) characterization of TiO2 nanotube arrays.  Nano-




   
Figure 3.2.  Neural Stem/Progenitor Cells immunocytochemically labeled with antibodies to determine 
phenotypes of differentiated cells.  DAPI was used to label DNA in nuclei.  No drastic changes in 
morphology or differentiation were apparent.  However, there appeared to be fewer NSCs on the 
glass substrates compared to the nanotube arrays.  (Scale bar = 100 µm) 
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Figure 3.3.  Cell density was statistically similar between glass coverslips and nanotube array sub-






   
 
Figure 3.4.  The differentiation of NSC on 60 nm Nanotubes compared to glass coverslips.  Statisti-
cally similar percentages of TUJ1 and RIP positive cells were observed.  However, fewer astrocytes 
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4.1. Abstract 
The differentiation and proliferation of neural progenitor cells (NPCs) are dependent on various in vivo 
environmental factors or cues, which may include an endogenous electrical field (EF), as observed 
during nervous system development and repair.  In this study, we investigate the morphologic, pheno-
typic, and mitotic alterations of adult hippocampal NPCs that occur when exposed to two EFs of 
endogenous strength.  NPCs treated with a 437 mV/mm continuous EF aligned perpendicularly to the 
EF vector and had a greater tendency to differentiate into neurons, but not into oligodendrocytes or 
astrocytes, compared to controls.  Yet fewer cells were observed in the continuous EF, which in part 
was due to a decrease in cell viability.  A 46 mV/mm alternating EF was applied to determine if an 
alternating EF could cause changes in NPC differentiation.  However, the alternating EF of this mag-
nitude showed no major differences, compared to control conditions.  Similarly, the percent of mitotic 
cells during the last 14 hours of the experiment was not statistically different between all treatments.  
To our knowledge, this is the first evidence demonstrating the effects of EFs on the differentiation of 
NPCs.  Further investigation and application of EFs on stem cells is warranted to elucidate the utility 
of EFs to control phenotypic behavior.  With progress, the use of EFs may be engineered to control 
differentiation and target the growth of transplanted cells in a stem cell-based therapy to treat nervous 
system disorders. 
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4.2. Introduction 
Endogenous EFs occur during development of the central nervous system (CNS) 254, 255, in wound 
healing 136 and in the healthy 256 or highly active epileptic adult brain 257, 258  So, both in development 
and in the adult endogenous electric fields can be found.  In the adult, evidence of EFs has been 
demonstrated from recording of extracellular potential gradients of the hippocampus.  In a isolated 
intact or “injured” hippocampus an outward and inward current were recorded, respectively 259.  In 
vivo hippocampal recording of steady potential gradients of 4 mV/mm have been recorded under 
physiological conditions 256; from 0.5 to 4 mV/mm during normal slow wave activity 260, 261; and up to 
50 mV/mm after induced synchronous activity of granule cells 262.  During epileptic seizure, steady 
potential gradients of 10 mV/mm 257 and EFs up to 20 mV/mm 258 were recorded. These EF are very 
important, as disruption of endogenous EF causes developmental abnormalities demonstrated in 
chick and Xenopus embryos 255, 263; and reduces the rate of wound healing 136.  Also, drastically im-
portant for proper generation, repair or maintenance of the nervous system are neural progenitor or 
stem cells  (NSCs) 46 which proliferate and differentiate into neurons and glia 8-11.  In the adult brain, 
one of the areas known to contain neural progenitor cells (NPCs) is the hippocampus 46, 264.  These 
adult NSCs may be influenced by the endogenous EFs.  For example, rat models with varying de-
grees of status epilipticus (continuous seizure) all had increased neurogenesis in the adult dentate 
gyrus in the hippocampus, and the survival of these neurons depended on the degree of seizure se-
verity or activity 131.  Similarly, after stroke 265 or in hypoxic ischemia 266, NPCs have been shown to 
migrate, differentiate and integrate in areas of the brain where they otherwise would not.  Could oc-
currences of endogenous EF be another cue that alters the residing population of adult NPCs; for 
example to induce differentiation, migration and integration in the developed nervous system in learn-
ing, or to ameliorate nervous system damage? 
To our knowledge, the analysis of adult NPC differentiation, alignment, proliferation, and viability in an 
in vitro culture system within an EF have not been investigated.  The application of EFs on nervous 
system cells has been predominantly on amphibian cells 135, 197, 198, 200, 255, 267, 268, but response of cells 
to EF exposure is not the same for all cell types or species 136.  Culture of mammalian CNS cells in 
EFs has been previously explored.  Embryonic hippocampal neurons were subjected to EFs of 28 to 
219 mV/mm 193 and astrocytes with 500 mV/mm 269, in both cases cellular alignment became perpen-
dicular to the EF vector. Recently, EFs of 50, 100 and 250 mV/mm directed migration of NSPCs 
(emerging out of neurospheres) towards the cathode, in a dose dependent manner and that migration 
was dependent on N-methyl-D-aspartate receptors 270.  However, the role of EFs on the differentiation 
of multipotent stem cells is unknown.  Here, the extent of NPC exposure to EFs surpasses that of the 
sole study performed on NSPCs 270 by three days.  Our objective was to investigate and characterize 
the effects of EFs on NPCs, and to assess our ability to use EFs to control their differentiation and 
proliferation.  Furthermore, NPC migration occurs after injury in the brain 265, thus increasing the 
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amount of NPCs that reach the site of injury using an EF would be beneficial.  The application of an 
EF may amplify the therapeutic ability that NPCs exercise on the CNS.  The utilization of EF treat-
ment combined with stem cell therapy may become a rational strategy to facilitate neuro-regeneration 
and repair in order to treat a variety of neurodegenerative diseases and CNS injury (Alzheimer’s or 
Parkinson’s disease, spinal cord injury and other previously non-treatable damages to the CNS 1, 63, 
135, 223, 225, 226).   
4.3. Materials and Methods 
4.3.1. Neural Progenitor Cell Cultures 
Neural progenitor cells (NPCs) were a generous gift from Dr. F. Gage (Salk Institute for Biological 
Studies, La Jolla, CA). The NPCs were isolated from the dentate gyrus of the hippocampus of adult 
Fischer 344 rats as reported by Palmer and colleagues 23.  The NPCs were maintained in 75 cm2 
tissue culture flasks (T-75; Fisher Scientific, Pittsburgh, PA) coated with poly-L-ornithine (10 µg/mL; 
Sigma) and mouse-derived laminin-1 (5 µg/mL; BD Biosciences, Bedford, MA) in phosphate-buffered 
saline (PBS; Invitrogen, Carlsbad, CA).  The NPCs were maintained under proliferating conditions by 
culturing in ‘’complete medium” containing Dulbecco’s modified Eagle’s medium/Ham’s F-12 
(DMEM/F-12, 1:1; Omega Scientific, Tarzana, CA) supplemented with N2 (Gibco BRL, Gaithersburg, 
MD), 20 ng/mL basic fibroblast growth factor (human recombinant bFGF; Promega Corporation, 
Madison, WI), and 2.5 mM L-glutamine (Gibco BRL, Gaithersburg, MD).  For in vitro analysis, NPCs 
were detached from a T-75 flask using 0.05% Trypsin-EDTA (Gibco BRL, Gaithersburg, MD), har-
vested and collected by centrifugation at 1000g for 5 minutes.  The pellets were re-suspended and 
triturated gently in complete medium without bFGF and with 5% FBS.  NPCs were then seeded at 
100 cells/mm2 within stimulation chambers for experimental observation.  Culture conditions main-
tained at 37°C in a 5% CO2 / 95% humidified air atmosphere for 6 days in culture medium.  Culture 
media was replenished every two days.   
4.3.2. Stimulation Apparatus 
Electric field exposure chambers were constructed based on work described by McCaig et al. and 
Alexander et. al. 189, 269, but modified for sterile mammalian cell culture over an extended period.  
Stimulation chambers were created by adhering machined Lexan® polycarbonate pieces with two 0.3 
mm x 14.5 mm x 40 mm recesses (Figure 4.1, A and B) to 50 mm x 70 mm glass slides using Syl-
gard.  Ag/AgCl electrodes were placed in 25 mL bottles containing Dulbecco’s modified Eagle’s 
medium/Ham’s F-12 (DMEM/F-12, 1:1; Omega Scientific, Tarzana, CA) with penicillin (100 IU/mL), 
and streptomycin (100 µg/mL) on both sides of the chamber.  The electrodes were provided a con-
stant electrical current from an electrophoresis system power supply (FB 600; Fischer Scientific, 
Pittsburg, PA). Glass tubes containing 1% agarose (42°C gelation temp; Sigma-Aldrch, St. Louis, 
MO) gels made in Dulbecco’s modified Eagle’s medium/Ham’s F-12 with 5% Fetal Bovine Serum 
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(FBS, Atlanta Biologicals Inc., Laurenceville, GA), penicillin (100 IU/mL) and streptomycin (100 
µg/mL) connected the electrodes to wells containing media that supplied the NPCs in the apparatus 
(Figure 4.1, C).  The electrodes convert the electron current to a Cl- ion flow from the cathode to the 
anode through the agarose gel bridge.  The ion flow generated a consistent EF through the media. 
The strength of the EF (E) produced was calculated by the formula: E = Iρ/A, using the intensity of the 
electric current (I), the resistivity of the media (ρ = 655 ± 6 Ω•mm), and the cross sectional area of the 
chamber (A= 4.35 mm2).  The resistivity of the media at 37°C was measured using a conductance 
meter (YSI 35; YSI, Inc., Yellow Springs, OH). 
The machined polycarbonate pieces and glass slides were cleaned by boiling in diluted RBS-35 de-
tergent concentrate (Pierce, Rockford, IL).  They were then rinsed repeatedly with purified, filtered 
water (18 MΩ Millipore, Billerica, MA) and sterilized by exposure to UV light for 30 minutes.  Each 
glass slide was aligned to the longest side of its corresponding machined polycarbonate part before 
adhering the two parts.  After allowing the adhesive to dry for two days, 70% ethanol was flushed 
through the chambers and the apparatus was rinsed with distilled water (Gibco BRL, Gaithersburg, 
MD).  Chambers were then coated with poly-L-lysine (100 mg/mL) and laminin-1 (10 mg/mL). NPCs 
(with culture media) were seeded at a concentration of 100 cells/mm2 on the glass slides within 
chambers. 
4.3.3. Electric Field Treatment 
NPCs were treated with two different EFs of physiological strength 135, 136: a 46 mV/mm alternating EF 
(0.338 mAmps) with a 30 minute period and square bi-polar waveform, and 437 mV/mm continuous 
EF (3.383 mAmps).  The magnitude of EFs in embryos are typically less than 100 mV/mm 271 but 
approximately 1800 mV/mm across the neural tube 272.  In vitro, the effects on mammalian brain cells 
have been investigated for EFs between 1 and 500 mV/mm 193, 273-275, thus we chose to stay within 
this range.  The alternating EF frequency was chosen based on EF treatment of spinal chord injury in 
clinical trials 133.  The alternating and continuous EF treatments were applied to the NPCs using a 15 
MHz waveform generator (Hewlett-Packard Company, model 3321A; Palo Alto, CA) electrophoresis 
power supply (FB600 and for time-lapse FB 452; Fisher Scientific Pittsburg, PA), respectively.  EF 
treatment began 4 to 6 hours after NPCs were seeded in the chambers.  The continuous EF treat-
ment was applied for 16 to 24 hrs a day for the first 3 days, and on the final day of each experiment.  
To avoid electrode exhaustion in the continuous EF treatment, electrodes were alternated as the 
positive and negative electrode (while maintaining the EF vector direction by rotating the chambers 
180 degrees) after each day of stimulation.  Media in the electrode-containing bottles was replaced 
after pH changes were noticeable, due to extended stimulation.  The alternating EF was applied for 
the duration of each experiment.  NPCs in control conditions did not receive EF treatment but were 
cultured in the custom culture apparatus.  Culture media in the chambers (where the NPCs resided) 
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was replenished every two days.  NPCs were maintained at 37°C in 5% CO2 / 95% humidified air 
atmosphere for the entire 6 days in vitro (DIV). 
4.3.4. Cell Viability 
Lactate dehydrogenase (LDH) assay kit from Sigma-Aldrich (St. Louis, MO) was used to determine 
the viability of cells after one day of treatment.  LDH content in the media of each experimental condi-
tion was determined colorimetrically.  Colorimetric readings were normalized between 0 and 1, 
corresponding to positive and negative controls, respectively.  Positive controls consisted of killed 
cells using 0.2% triton-X-100 in media.  Negative controls were NPCs in the apparatus that received 
no EF treatment.  Cell density was determined along with immunocytochemical quantification (see 
below).   
4.3.5. Immunocytochemistry 
After 6 DIV, cells were immunochemically processed.  Briefly, the media was removed with two dilu-
tions of 0.1 M PO4 buffer, and NPCs were fixed on the 50 x 70 mm2 glass slides using 4% 
paraformaldehyde in 0.1 M PO4 buffer, and rinsed in filtered PBS 7 times with 5 minutes rinses.  Cells 
were then incubated in blocking solution {5% normal donkey serum, 0.4% bovine serum albumin 
(BSA; Sigma), and 0.2% Triton X-100 (Fisher Scientific)} for 120 minutes.  Cell type specific antibody 
markers were used to identify differentiated NPCs.  Early neurons were identified using anti-class III β 
tubulin (TUJ1, mouse monoclonal IgG; R&D systems, Inc., Minneapolis, MN); oligodendrocytes, anti-
RIP (mouse monoclonal IgG; Developmental Studies Hybridoma Bank); and astrocytes, anti-glial 
fibrillary acidic protein (GFAP, mouse monoclonal IgG; ICN, Costa Mesa, CA) were used.  Primary 
antibodies, TUJ1, RIP and GFAP were diluted with blocking solution at 1:500, 1:1500, and 1:600, 
respectively.  Additionally, bromodeoxyuridine (BrdU), a thymidine analogue that incorporates into 
DNA during the S phase of mitosis, was added to all experimental conditions 14hrs before the end of 
experiments.  The cells which had incorporated BrdU were identified with a primary antibody against 
BrdU (anti-BrdU, rat monoclonal IgG; Abcam Inc., Cambridge, MA) diluted with blocking solution to 
1:200. 
The area of each glass slide containing cells within the chambers was divided using a PAP Pen 
(Electron Microscope Sciences, Hatfield, PA) to apply the different phenotypic antibodies aforemen-
tioned; anti-BrdU was typically used in combination with the phenotypic primary antibody.  Cells on 50 
x 70 mm2 glass slides or coverslips were incubated in primary antibodies overnight at 4°C in a humid 
chamber and repeatedly rinsed in PBS.  Next, cells were incubated in the appropriate biotinylated 
secondary antibodies and 4’, 6-diamidino-2-phenylindole, dilactate (DAPI), at 1:60 in blocking solution 
for 90 minutes and rinsed.  Finally, cells were incubated in the dark with streptavidin-conjugated Cy3 
(Jackson ImmunoResearch, West Grove, PA) for 30 minutes, at 1:15,000 in PBS.  Additionally, Cy5 
(Jackson ImmunoResearch, West Grove, PA) was used to indicate anti-BrdU immunoreactivity.  The 
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50 x 70 mm2 glass slides containing cells were then rinsed repeatedly with PBS and mounted onto 
microscope slides using Gel Mount (Biomeda Corp., Foster City, CA). 
4.3.6. Microscopy 
Cells were observed using light microscopy (Nikon Diaphot-TMD bright field/phase contrast micro-
scope) during culture.  Images were captured with a charge-coupled device camera (Megaplus; 
Model 1.4; Kodak Corp., San Diego, CA) connected to a frame grabber (Megagrabber; Perceptics, 
Knoxville, TN, in a Macintosh computer; Apple Computer, Cupertino, CA) using NIH Image 1.58VDM 
software (Wayne Rasband, National Institutes of Health, Bethesda, MD).  For immunocytochemical 
labeling, a Nikon TE2000 (Nikon Corp., Melville, NY) inverted microscope equipped with standard 
epifluorescence illumination and a cooled digital camera (Cascade® 512B or Coolsnap® EZ; Pho-
tometrics, Tucson, AZ) controlled by MetaMorph software (Universal Imaging Corporation, West 
Chester, PA) was used.  Time-lapse videos were captured with a cooled mono-chrome 12-bit digital 
camera (Retiga; QImaging, Surrey, Canada), mounted on a Leica DMIRE2 (Leica Microsystems, 
Wetzlar, Germany) controlled through OpenLab v. 3.5.1. 
4.3.7. Quantitative Analysis of Immunocytochemistry 
Images of NPCs in the chambers were captured where the EF would be uniform in the EF treated 
experimental conditions (as indicated Figure 4.2, A).  Ten to twelve areas were analyzed per primary 
antibody.  Two to three images were taken for each field analyzed, corresponding to fluorescent 
emissions of DAPI, CY3 and/or CY5.  Nuclei and immunoreactive (IR) cells were counted semi-
automatically using Image J 214.  The sum of IR cells was divided by the sum of nuclei (DAPI-labeled) 
for all images per treatment to determine the percentage of immunoreactive cells for each primary 
antibody.  In other words, the percentage of NPCs that differentiated into neurons, oligodendrocytes 
and astrocytes after 6 DIV and those that were proliferating 14hrs before the end of the experiment, 
were determined for each experimental condition.  The background or non-specific immunoreactive 
intensity was determined from cells that were exposed to fluorescent secondary antibodies 
(CY3/CY5) only.  Only immunoreactive cells with emission intensities above the non-specific intensity 
threshold were counted.  JMP version 8.0.1 (Copyright © 2006 SAS Institute) was used to analyze 
the data collected for all experiments.   
4.3.8. Image-J Semiautomatic Quantitative Analysis 
In an attempt to automate cell counting, a macro was programmed using ImageJ 214.  Images were 
processed in batches, and for each image the background fluorescence was subtracted, DAPI/anti-
BrdU immunoreactive nuclei that were approximately 15 to 315 µm2 were encircled, and counted 
automatically.  The procedure was semi-automatic, as user intervention was required to determine 
the total cell count by manually counting nuclei with low fluorescent intensity, clumped nuclei, and/or 
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areas out of the specified range.  For each experimental condition, all nuclei counted were summed 
to determine the number of cells examined.  Likewise, BrdU-immunoreactive (IR) nuclei were semi-
automatically counted using the macro created for ImageJ.  The total DAPI stained nuclei divided by 
the total actual area photographed yielded the cell density (cells per mm2) for each treatment. 
4.3.9. Quantitative Analysis of Cell Morphology 
To determine cellular alignment, images were processed using ImageJ (NIH).  Briefly, images were 
converted to 8-bit after thresholding image brightness to make the cellular processes of each cell 
visible.  The Particles8 plug-in for ImageJ 276 was used to determine the angle between the longest 
axis of each cell with the horizontal of the image.  Cell angles were then adjusted relative to the EF 
vector, absolute from 0° to 90°, with 0° and 90° indicating cellular alignment parallel and perpendicu-
lar to the EF vector, respectively.  For clarity, the outline of a cell at 6 DIV and the angle, θ, made by a 
line between its furthest points with the EF is shown (Figure 4.2, A).  Furthermore, primary processes 
emanating from cells were counted and separated into quadrants as shown in Figure 4.3, similar to 
Cork et al. 192.  Alignment and process count data were pooled from all experiments and the distribu-
tion for each experimental treatment was determined.  
4.4. Time-lapse Digital Imaging and Quantification of Migration 
Similarly, the migration rate was determined from time-lapse images using the Manual Tracking plug-
in for ImageJ 277.  Time-lapse recordings were initiated 6-12 hours after NPCs were plated into cham-
bers, with images captured every 5 minutes for 12-36 hours.  Cells were maintained in the custom 
chamber, on a heated stage at 37°C.  All media were supplemented with 10 mM HEPES.  A thin film 
of mineral oil was used to prevent evaporation and changes in pH due to gas exchange at the media-
air interface, similar to 273.  Cell migration was quantified as shown by Yao et. al. 274. Briefly, the dis-
tance of cell displacement was measured as the length between starting point and the final cell 
position of the migrating cell (in μm).  It was calculated from pixel coordinate data using the Pythago-
rean theorem.  The rate of cell displacement was calculated based on the distance of cell 
displacement in a given time.  The cell track velocity was calculated from the full distance of cell mi-
gration in a given time.  Finally, the mean directedness index of total cell movement was calculated 
from ∑i cosΦi/N, where Φ is the angle between the EF vector and the cellular translocation direction, 
and N is the total number of cells from at least three experiments.  Thus, the mean directedness in-
dex would equal 1 or -1 if all cells migrated directly toward or away from the cathode (-), respectively.  
4.4.1. Statistical Analysis 
ANOVA was performed on data of antibody marker counts (e.g. – TUJ1, RIP, GFAP and BrdU), cellu-
lar alignment angles, and all quantities derived from time-lapse digital imaging.  The EF treatment and 
the date of each experiment were set as fixed and random effects, respectively.  To determine statis-
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tical significance, a student’s t test was used with adjustments for the p-values using the Bonferroni’s 
Method.  A Chi-Squared test was performed to determine if the angle of cellular alignment was evenly 
distributed for each EF treatment.  JMP (v. 8.0.1) or SAS (v. 9.1) (Copyright © 2006 SAS Institute), 
were used to analyze the data collected for all experiments. 
4.5. Results 
4.5.1. Cell Alignment 
The cellular alignment of NPCs relative to the EF vector is displayed in Figure 4.2.  The alignment of 
each NPC’s longest axis was evaluated for 1648, 910, and 880 NPCs cultured in a 437 mV/mm con-
tinuous EF, 46 mV/mm alternating EF or no EF, respectively (n = 4).  The data revealed an uneven 
distribution (chi-squared test for equal proportions, p < 0.0001) with the majority of NPCs aligned 
perpendicularly to the EF vector (49.1% between 70° and 90°, compared to only 5.3% of NPCs that 
aligned between 0° and 20°).  In contrast the distributions of the alternating and non-stimulated condi-
tions were approximately even (Chi-squared test for equal proportions, p = 0.1614 and 0.7891).  
Comparisons between the control and alternating conditions revealed no statistically significant differ-
ences in alignment.  The cellular alignment in the continuous EF was significantly greater compared 
to non-stimulated and alternating EF conditions (p < 0.001).  The trend towards perpendicular align-
ment of NPCs in the continuous EF and the contrast between this and the other conditions is clearly 
evident in Figure 4.2. 
4.5.2. Process Growth Inhibited Anodally and Promoted Perpendicularly  
We quantified the number of processes emanating out of the NPC somas and grouped these counts 
into quadrants.  The quadrants corresponded to the anode (+),cathode (-), left and right facing sides, 
as shown in Figure 4.3, A.  Since the control and 40 mV/mm alternating EF were similar in alignment, 
only cells cultured without EF and in the 437 mV/mm EF treatment were analyzed.  From the analysis 
(Figure 4.3, B) it was determined that significantly fewer primary processes emanated out toward the 
anode facing side (+) compared to the cathode (-) and the mock anode on NPCs in control conditions 
(0.63 ± 0.09 vs. 0.97 ± 0.03 and 1.12 ± 0.11, respectively; p<0.0001, n=4).  Furthermore, significantly 
fewer processes emanated from sides of the soma perpendicular to the EF vector, compared to con-
trol cells (left side – 1.38 ± 0.10 vs. 1.13 ± 0.12, right side - 1.28 ± 0.13 vs. 1.08 ± 0.14 , respectively; 
p<0.0001, n=4).  Results were similar when comparing the left and right sides to the cathode and 
anode sides for cells treated with the 437 mV/mm EF (p<0.0001).  Thus, in an EF, process growth is 
promoted at sides that are perpendicular to the EF, and inhibited at the anode (+) facing side.   
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4.5.3. EF Influences NPC Differentiation 
For each condition, fluorescent microscope images were analyzed for nuclear labeling with DAPI and 
primary antibody (TUJ1, RIP, GFAP, and BrdU) immunoreactivities (Figure 4.4).  Cells immunoreac-
tive for the primary antibody and the total DAPI and BrdU were counted.  
The percentage of NPCs that differentiated into each of the three neural phenotypes was determined 
(immunoreactive cells for each phenotypic primary antibody) and divided by total DAPI labeled nuclei 
(Figure 4.5).  The least squared mean percentages of TUJ1 immunoreactive cells for the control, 46 
mV/mm  alternating and 437 mV/mm continuous EF conditions were found to be 24.1 ± 1.7% (± 
S.E.M.), 23.8 ± 1.9% and 41.7 ± 2.2%.  The percentage of immunoreactive TUJ1 cells is significantly 
greater in the continuous EF conditions when compared to control and alternating EF conditions (n = 
6, p < 0.001).  The percentage of  RIP immunoreactive cells for the control, 46 mV/mm alternating 
and 437 mV/mm continuous EF conditions were 24.5 ± 3.6%, 22.3 ± 3.1% and 18.6 ± 3.5%, respec-
tively.  Finally, the percentages of GFAP immunoreactive cells in the control, 46 mV/mm alternating 
and 437 mV/mm continuous EF groups were 13.7 ± 2.3%, 9.6%  ± 3.7% and 14.9%  ± 4.4%.  The 
least mean square percentage of RIP and GFAP immunoreactive cells was statistically consistent 
over the three conditions. 
4.5.4. Bromodeoxyuridine (BrdU) Cell Birth-Dating Analysis 
Bromodeoxyuridine was used to label newly generated cells during the final 14 hours of cell culture.  
The percentages of cells immunoreactive for BrdU was 19.1 ± 6.7%, 29.7 ± 6.7%, and 31.7 ± 7.6% (n 
= 3) for the control, alternating EF, and continuous EF treatments, respectively.  Statistical analysis 
revealed no significant difference in proliferation between the cells with and without EF treatment 
(Figure 4.6, B). 
4.5.5. Cell Density 
After 6 DIV, cell density was assessed by determining the number of DAPI labeled nuclei in the area 
of each image (Figure 4.6, A).  The continuous EF treatment had a significantly lower number of cells 
per area, 136 ± 45 cells/mm2 compared to the control, 268 ± 45 cells/mm2 (n=6, p = 0.017).  However, 
no significant differences were observed between the control and alternating EF (209 ± 41 cells/mm2).   
4.5.6. Lactate Dehydrogenase Assay 
To determine if NPC viability was being negatively affected by the EF treatment, the amount of lactate 
dehydrogenase (LDH) was assayed, after 1DIV.  The data revealed significantly greater LDH content 
in the 437mV/mm EF treatment compared to the control (17.8 ± 4.0 vs. 0.0 + 4.0 %, respectively; 
n=3, p=0.001).  In contrast no statistical difference was observed between cultures of NPCs not 
treated with an EF and treated with a 46 mV/mm alternating EF (3.2 ± 5.2%). 
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4.5.7. EF Influences NPC Migration 
We examined NPC migration in control and continuous EF treatments for 8 hours via time-lapse digi-
tal imaging.  The alternating EF was not analyzed because of its similarity to control conditions.  
Clearly the superimposed paths of migrating NPCs (Figure 4.7, A) indicate that EF influenced and 
directed the migration of adult NPCs.  NPCs were displaced an average of 114.2 ± 15.4 μm from the 
origin in the 437 mV/mm EF, which was significantly further than in control conditions (32.7  ± 19.0 
μm (p = 0.0242; Figure 4.7, B).  The direction of migration (Figure 4.7, C) was significantly greater 
towards the cathode (-) in the continuous EF than in controls (Directedness index- 0.43 ± 0.3 vs. 0.01 
± 0.04, respectively; p = 0.001).  At 8 hours, the mean track velocity in the 437 mV/mm continuous EF 
was, surprisingly, not significantly different than in controls (26.1 ± 1.6 vs. 24.1 ± 2.0 μm/h, respec-
tively; Figure 4.7, D).  Similarly the displacement rate during each 5 min interval averaged over 8 
hours, was also not significantly different between conditions (28.9 ± 3.4 vs. 24.1 ± 3.0 μm/h, respec-
tively, p =0.18; Figure 4.7, E). 
4.5.8. Changes in Migration Depend on Exposure Duration 
To determine if changes in migration parameters were dependent on the duration of EF treatment, 
each time interval was analyzed during the first 85min.  Time dependence analysis revealed that 
characteristics of migration were dependent on EF exposure duration and became asymptotic after 
approximately 30min (Figure 4.7, F and G).  Differences in directedness between EF and the control 
conditions increased with time and were significant from 5 min (p=0.0025, 408 cells; Figure 4.7, F) 
onwards.  Similarly, for displacement, significant differences were observed starting at 25min (p 
=0.010, 405 cells; Figure 4.7, G).  In both cases, directedness and displacement differences became 
very significant with an additional 5 min (p<0.0001, n=3, student t-test).  However, significant differ-
ences were not observed between NPC track velocity in the continuous EF compared controls (data 
not shown).   
4.6. Discussion 
We have investigated and observed how EFs affect mammalian NPCs.  To our knowledge, this is the 
first study to examine the effects of EF exposure on the differentiation into CNS phenotypes (neurons, 
oligodendrocytes, and astrocytes), proliferation and viability of adult mammalian NPCs.  Only one 
other study explored changes in cellular viability due to EFs treatment in vitro 278.  Our alignment re-
sults are in agreement with the majority of prior investigations of mammalian nervous system cells 
treated with EFs, which aligned perpendicular to the EF vector in a continuous EF. 
4.6.1. Electric Field Induced Neurogenesis  
The preferential differentiation of EF-treated NPCs into neurons agrees with similar published results 
for PC12 cells.  Yet PC12 cells, are derived from an adrenal tumor, and when exposed to nerve 
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growth factor (NGF) develop into cells with the capacity to sprout neurites, generate action potentials, 
and form synapses.  In an EF, PC12 cells developed into neurons without the use of NGF 163.  How-
ever, PC12 cells do not have the potential to become oligodendrocytes or astrocytes like multipotent 
NPCs.  EFs may promote the differentiation into neurons by depolarizing transmembrane potential; in 
similitude to culturing NPCs in media with an elevated K+ concentration, which depolarizes NPCs and 
increases the differentiation into neurons 279. 
Indirect influence on the differentiation of NPCs could potentially be attributed to EF effects on differ-
entiated astrocytes and oligodendrocytes.  Astrocytes have been shown to release greater quantities 
of NGF when stimulated with an EF 186.   We can speculate that endogenous EF may also indirectly 
influence NPCs to differentiate into early neurons or mature into neurons through increased astrocytic 
production and secretion of the potent neurogenic growth factor, NGF.  Thus, the endogenous EF 
found in development 254, 255 or after injury to the nervous system 259 may favor the production of new 
neurons by influencing NPCs synergistically via membrane potential depolarization 280, 281 and in-
creased neurogenic receptor stimulation (increased neurotrophic factor secretion by mature nervous 
system cells influenced by the endogenous EF).  However, there are a multitude of receptors poten-
tially involved in galvanotaxis and galvanotropism, which are also related to NPC differentiation.  For 
example, N-methyl D-aspartate (NMDA) receptors were recently demonstrated to be involved in the 
directed migration of micro-explants containing NSPCs 270, and augmented stimulation of NMDA re-
ceptors increased proliferation and neuronal differentiation in the adult hippocampus 282.  Thus, NPC 
migration and neuronal differentiation seem to be linked together at least through the NMDA receptor.   
Our work creates a stronger link between the electrical activity in the adult mammalian brain (normal 
or injured) and the resident populations of NPCs.  The increase we see in neuronal differentiation 
agrees with increased neurogenesis in the hippocampus of epileptic models 131, where elevated firing 
of neurons produces an extracellular electric potential 257, 258, 283.  What has not been previously al-
luded to is that, in the hippocampus, the differentiation of NPCs into oligodendrocytes or astrocytes 
may not be altered by extracellular EF activity (applied or created by heightened neuronal activity), as 
indicated by our results.  Thus, it is seems that neurogenesis is favored in an endogenous EF in the 
adult CNS.  Indeed, transplanted neural human stem cells into the brains of epileptic rat models pro-
duced inhibitory interneurons that reduced seizure reoccurrence 284.  Furthermore, it may be that 
injury induced EFs promote the production of new neurons, partially compensating for an environ-
ment conducive to active gliosis and glial scar formation 243-245.   
4.6.2. Aligned Morphology 
The overall alignment of NPCs was visibly perpendicular to the continuous EF vector as shown in 
light microscopy images taken throughout the 6 days in vitro (DIV) and in the fluorescent microscope 
images obtained after immunostaining procedures at 6DIV (Figure 4.4).  Moreover, a greater number 
of processes were observed emanating out of NPCs on the sides perpendicular/lateral to the EF 
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compared to other sides in the 437 mV/mm EF and controls.  In agreement, EF treated cultures of 
disassociated rat brain cells, such as astrocytes 269, 273 and neurons 193, grew perpendicular to the EF 
vector.  The perpendicular alignment of neonatal rat cortical astrocytes was proportional to the EF 
strength or time of exposure, with a maximum response at 500 mV/mm for 10hours 273.  Similarly, 
Alexander et. al. demonstrated that astrocytes aligned perpendicularly to the EF vector when ex-
posed to an EF of 500 mV/mm, for a duration of 24hrs 269.  Furthermore, the presumptive axons of rat 
hippocampal neurons derived from 18-day-old fetus aligned perpendicularly to the EF vector in EF of 
29-290 mV/mm, but were not affected by EFs of less than 9 mV/mm 188.  Thus, the results found in 
literature agree that mammalian brain cells align perpendicularly in an EF as is seen in this study.  It 
seems that the ionic distribution inside the cell is changed the least at the sides of the cell that are 
perpendicular to the EF 280.  Therefore, if changes in the trans-membrane potential negatively affect 
process growth, then process growth would be least likely to change perpendicular to the EF vector. 
In addition to the longest axis aligning perpendicularly, we qualitatively (Figure 4.2, C) and quantita-
tively (Figure 4.3, B) determined that fewer primary processes emanated out of the anode facing side 
(+) compared to all other sides of NPCs in the 437 mV/mm EF, and the mock anode facing portion of 
NPCs in control conditions.  Thus, process growth is inhibited at the anode-facing side of the cell in 
an EF.  Growth was definitely not promoted at the cathode (-) facing side, as the number of proc-
esses were the same on the side of NPCs that faced the mock cathode in controls.  Furthermore, 
cathodally directed processes were not qualitatively more robust or longer than processes emanating 
from other areas.  Without a proper simultaneous morphologic analysis of EF treated and non-treated 
cells, claims of promoted cathodal growth 274 are not as conclusive.  Thus, we are in disagreement 
that an EF would make process growth faster at the cathode (-) facing side.  Some controversy sur-
rounds the use of EFs and the claim that neural processes (neurites) grow faster in an EF 191, 271.  
Similar effects have been observed for neurite growth of PC12 cells 192, where alignment was de-
scribed to be both perpendicular and toward the anode (+) when exposed to a 30 mV/mm EF for 
48hrs.  Decreased cytoskeletal architecture (decrease in actin polymerization) in human umbilical 
vein epithelial cells 285 and in human mesenchymal stem cells and osteoblasts 286 demonstrate one 
reason for inhibited growth on the anode (+) facing side of cells.  Changes in intracellular Ca2+ con-
centration indicate that the Ca2+ channels are mechanistically involved in directed growth and 
migration of cells in EFs.  Recently, neonatal rat hippocampal neurons (dissociated from micro ex-
plants) exposed to EFs up to 300 mV/mm for 1 - 1.5 hours directed their golgi, nucleosomes, 
neurites, and migration asymmetrically toward the cathode 275.  Besides these morphological results, 
mild turning of cathodal processes was qualitatively observed, not as drastic as observed for 
Xenopus neurons 188. 
The mechanism for alignment, migration and differentiation most likely involves membrane receptor 
movement due to electrophoresis and electro-osmosis (competing forces) 199.  These two forces are 
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considered to cause the migration of different receptors towards the electric poles 135, 287 depending 
on the size and charge of the receptor.  Plus, an asymmetric charge distribution of the transmem-
brane potential 281 may slightly inhibit or facilitate the opening of ion channels, depending on which 
electrode the membrane is facing.  There are potentially many membrane components involved in 
induced neuronal differentiation and directed migration of NPCs, such as Ca2+ channels 202, 288 and 
NMDA 270, epidermal 289, 290, basic fibroblast 161 and transforming (β-1) 161, 235 growth factor, and ace-
tylcholine receptors 197.  Furthermore, EF induced directionality has been shown to be dependent on 
substrate 188, serum 161 and cell type 136, 271.   
4.6.3. Small Alternating EF has No Effect 
The frequency of the 46 mV/mm alternating EF was chosen based on clinical trials to treat spinal cord 
injury with an alternating EF applied in vivo in an attempt to guide the growth of motor neurons and 
restore function and sensation to patients 133.  The idea of switching the polarity every 15min was 
derived from the finding that “a small population of cultured Xenopus neurites was stimulated to grow 
cathodally upon switching EF polarity, while anodal inhibitory effects were delayed 291”. However, that 
observation was made upon a single reversal of polarity and has not been extended to long term 
exposure of Xenopus neurites to switched EF 271.  To our knowledge this is the first study to apply a 
slowly alternating EF to mammalian cells (where the polarity was switched every 15 min) and investi-
gate effects during 6 DIV.  Even though we used an alternating EF greater in amplitude than in 
clinical trials (46 mV/mm vs. 0.5–0.6 mV/mm 133, 271, respectively), it was surprising that there were no 
observed changes in NPCs in terms of alignment, differentiation, proliferation or viability in vitro 271.  
However, in the clinical trials, an alternating EF of lower strength was shown to have a slight regen-
erative effect 133.  
On the other hand, the majority of in vitro studies of mammalian nervous system cells cultured in EFs 
(ours included) dictate that cellular process growth will be perpendicular to the EF.  One might argue 
that an alternating EF may have been chosen by Shapiro et. al. in an attempt to align the growth of 
mammalian neurites parallel to the EF 133.  Whatever the reasoning, NPC did not align to an alternat-
ing EF after treatment.  Therefore, our results are in agreement with the argument that there is no in 
vitro basis for the therapeutic effects of an alternating EF used to treat spinal cord injury 271, when 
considering that the current used in the clinical trials was much lower than that of EF experiments in 
vitro described in literature.   
We must however, consider that in the clinical trials, the stimulation was spread over two years, which 
is much longer compared to this study, where the cells are maintained for only 6 DIV.  Thus, with 
time, a smaller EF may cause cellular changes in the surrounding tissue that are not noticeable or 
cannot be described by our experiments.   
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4.6.4. Directed Migration 
The 437 mV/mm treatment directed migration of NPCs cathodally (-), which agrees with the migration 
of embryonic derived NSPCs 270, neonatal neurons 274, and nineteen out of twenty-six reviewed cell 
types 136, cultured in EFs. Furthermore, the directedness and net displacement of migrating neonatal 
rat hippocampal cells, like that of our NPCs, was proportional to EF strength and treatment time 274.  
Here, NPCs were about 35 μm/h slower than neonatal rat hippocampal cells 274, but closely agreed 
with the velocity of rat embryonic NSPC in EFs 270.  Compared to controls, the velocity of EF treated 
NPCs was not significantly different at 8 hours, similar to that of neonatal rat hippocampal cells 274.  
However, the average track velocity became more similar between control and EF treated NPCs with 
time.  Early on, significant differences were observed 45 min after EF exposure commenced (ana-
lyzed with student t-test).  Although time-lapse micrographs were analyzed for only 8 hours, the 
response of NPCs during the 6 DIV is not expected to change drastically.  If anything, migration rate 
would probably slightly decrease due to process growth and increased adhesion as time progressed. 
Some cell types migrate toward the anode (+) while others are capable of dual-directional migration.  
For example, peripheral bovine lens epithelial cells migrated toward the cathode at 50 mV/mm and 
towards the anode at 150 - 250 mV/mm 292.  EF induced directionality has been shown to be depend-
ent on substrate 188, serum 161 and cell type 136, 271.  For example, Xenopus spinal cord neurons are 
known to migrate parallel to the EF or have neurites turn toward the EF vector 135, 194, 200, while 
Xenopus neural crest cells aligned perpendicularly to the EF 280.  Although, the mechanisms respon-
sible for regulating the directionality were not investigated in this work, this study demonstrates for the 
first time that EFs can be used to direct the migration of adult NPCs. 
4.6.5. Decreased Viability 
When treated with 437 mV/mm continuous EF, a noticeable decrease in cell density was observed as 
EF treatment progressed, leading to a significantly lower cell density (Figure 4.6, A) at the end of the 
experiment compared to chambers not treated with an EF.  Lower cell density has been attributed to 
a decrease in proliferation for human umbilical vein endothelial cells in a 200 mV/mm continuous EF 
applied for 72hr (3 DIV), but not for EFs of 50 or 100 mV/mm 278.  Therefore, one might anticipate a 
decrease in proliferation of NPCs in a stronger (437 mV/mm) EF applied for a similar duration.  We 
cannot conclude that there is a decrease in proliferation during the last 14 hours of the experiment 
(Figure 4.6, B).  It may be that during the first day of experimentation there is a decreased in prolifera-
tion, in addition to a decrease in cell viability as determined via LDH assay (Figure 4.6, C).  The 
accumulation of ions or electrode by-products in the bottles may begin to negatively affect the cells 
within 1 day of stimulation.  Since the media in the bottles containing the Ag/AgCl electrodes was not 
replaced before the pH changes reached the cells in the 437 mV/mm EF treatment, the methodology 
used to apply an EF may be less than ideal for extended stimulation and may require active monitor-
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ing of changes in pH.  Since, the 40 mV/mm alternating EF treatment did not show a significant de-
crease in cell density, it may be best to decrease the EF strength for the continuous EF treatment.  
The alternating EF strength could also be increased to elicit a response and eliminate the accumula-
tion of cation/ions at the negative/positive electrodes.  It should be noted that cellular density/viability 
in 437 mV/mm was too low to quantify any observations without the use of FBS. 
4.7. Conclusions 
This study supports the hypothesis that adult NPCs are affected both morphologically and phenotypi-
cally by an EF gradient.  Thus, endogenous EFs should be considered as a potential cue in the 
myriad of chemical, biological and physical cues present in the neurogenic niche.  As shown, adult 
NPCs in a continuous EF favored neuronal differentiation, but had no apparent effect on the differen-
tiation into other neural phenotypes.  This demonstrates that EFs may be useful when attempting to 
increase the number of neurons in neuron deficient tissue.  Our work shows the potential of using EF 
to control migration, differentiation and alignment of stem cells transplanted to treat nervous system 
disorders.  Surely, other electrical signal parameters should be investigated to determine if an electric 
signal can be tailored to produce a desired neural phenotype.  The tremendous therapeutic potential 
of stem cells may increase the efficacy of EFs used in treatments of nervous system disorders.  A 
broad range of work must be done to integrate transplanted adult NPCs and the application of an EF, 
but such a combination may potentially develop into an indispensible therapeutic approach for the 
treatment of the CNS.  
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Figure 4.1.  Apparatus used to treat NPC with EFs.  Modified computer aided drawing (courtesy of D. 
Jones, Ames National Lab, Iowa) of designed Lexan® polycarbonate (General Electric; Schenectady, 
New York) pieces with three machined holes and two recesses (B).  Once adhered to 50 mm x 70 
mm glass slides, the recesses become chambers of 0.3 mm x 14.5 mm x 40 mm dimension with the 
holes serving as media containing wells.  Glass tubes containing Agarose gelled media connected 
Ag/AgCl electrodes in culture media in 25mL bottle to each 28 mm x 13.5mm well that maintain the 
cells (C).  The culturing/stimulating chamber was housed in a 100 mm glass petri dish with modified 
lid for attachment of the stimulating electrodes. Electrodes were supplied via a function generator or a 
constant current source to create an EF. 
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Figure 4.2.  The angle (θ) of the longest axis with respect to the continuous EF vector (A) was deter-
mined, at 6 DIV, for NPC cultures without EF treatment, a 46 mV/mm EF (alternating every 15 
minutes) and a 437 mV/mm continuous EF, and distributed into bins of 10 degrees from 0 to 90 rela-
tive to the EF vector (B).  A chi-square test for equal proportions indicated that cellular alignment was 
evenly distributed in the control  and alternating EF groups, but not in the continuous EF group (p < 
0.0001, n = 4).  A significant difference in alignment was seen between the control and 437 mV/mm 
continuous EF (p < 0. 0001), and 46 mV/mm alternating EF and the 437 mV/mm continuous EF (p < 
0. 0001).  Similarly, superimposition of tracings of major cell processes (40 cells per condition) after 6 
DIV revealed that the majority of processes in the continuous EF treatment demonstrate perpendicu-
lar alignment to the EF vector (C).  Cell processes in the alternating EF at 40 mV/mm did not align in 
any direction with the EF vector, and were very similar to those without EF treatment (controls).   
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Figure 4.3.  Process growth is inhibited at the anode in an EF. Phase images of a control NPC (A1) 
and a NPC after 14 hours in a 437 mV/mm EF (A2).  Cells and their process were separated into 
quadrants using cross-hairs as shown in A.  The primary processes in each quadrant were counted 
and analyzed statistically for images taken at 3 DIV (B).  There were significantly fewer processes 
toward the anode (+) compared to the cathode (-) in the 437 mV/mm EF treatment♣ and controls*.  
Furthermore, a significantly greater number of processes were counted emanating from sides of the 
cell that were perpendicular to the EF vector (left and right), compared to cathode and anode facing 
sides♣ and the corresponding sides in controls* (* and ♣ indicate significance, p<0.0001, n=4, 225 
cells per treatment; Scale bar = 25 μm). 
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Figure 4.4.  Fluorescent microscopy images (20 X magnification) of immunoreactive cells labeled with 
the primary antibodies (TUJ1, RIP, GFAP, or BrdU) and nuclei stained with DAPI in three conditions: 
control (no electrical stimulation), alternating EF (46 mV/mm with oscillation of 15 minutes), and con-
tinuous EF (437 mV/mm). Each image was created by merging the three fluorescent channels: DAPI 
(blue), phenotypic antibody immunoreactivity (red) and BrdU immunoreactivity (green). 
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Figure 4.5.  Differentiation of NPCs cultured in two externally applied EFs, after 6DIV.  Phenotypic 
antibodies TUJ1, RIP, and GFAP were used to determine differentiation into early neurons, oligoden-
drocytes and astrocytes, respectively.  Differentiation into early neurons increased significantly when 
NPCs were exposed to an EF of 437 mV/mm compared to the 46 mV/mm alternating and control 
conditions (n = 6, *p < 0.001). 
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Figure 4.6.  Analysis of the effects of EFs on cell density, cell proliferation and cell death. (A) Expo-
sure to a 437 mV/mm continuous EF resulted in a significant decrease in cell density when compared 
to the control conditions (n=6, *p = 0.017).  (B) Percent of proliferative NPCs (positively labeled with 
BrdU) in the two types of externally applied EFs during the last 14 hours of the experiment.  No sig-
nificant differences in the average number of BrdU immunoreactive cells was observed when 
comparing the control to the 46 mV/mm alternating EF or the 437 mV/mm continuous EF (p = 0.103 
and 0.086, respectively. n=3). (C) Lactate dehydrogenase assay after 16-24 hours of EF treatment.  
Cell death is represented as a relative percentage between 0 and 100%, where 0 indicates the 
amount of cell death in the control group and 100% indicates complete cell death via culture media 
containing 0.02% Triton X.  Analysis reveals a significant difference in NPC viability between the 437 
mV/mm continous EF treated conditions and the control (n=3, p = 0.001). 
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Figure 4.7.  Time-lapse digital image analysis.  (A) The migration paths of 191 individual cells during 
the first 8 hours of EF exposure graphed to initiate at the origin and superimposed.  Migration was 
clearly directed towards the cathode (-) in the 437 mV/mm EF.  In contrast control cells migrated ran-
domly.  (B) After 8 hours EF, exposed NPCs were significantly further away from their origin 
compared to NPCs that did not receive EF treatment.  (C) The average direction of NPC migration 
was significantly more in the direction of the EF vector than in controls.  (D-E)  Neither the displace-
ment rate nor the mean track velocity of NPCs in a 437 mV/mm EF were different from control cells at 
8 hours.  (F)  Directedness was dependent on the time of EF exposure and peaked at approximately 
30 min.  Differences between EF and control conditions increased with time and were significant from 
5 min (p=0.0025, 408 cells) onwards (p <0.0001).  (G) The net displacement of NPCs away from the 
origin was dependent on time.  Significant differences between the displacement of control and EF 





   
CHAPTER 5: GENERAL CONCLUSIONS 
Overall, we have shown that control of neural progenitor cells (NPCs) can be achieved through ma-
nipulation of their surrounding environment with biological, physical and electrical cues.  We have 
demonstrated that NPC migration, alignment, cell viability, proliferation and differentiation can all be 
controlled externally.  The external cues used here provide spatial control over NPCs cultured on 
substrates, as opposed to soluble cues added to the media that do not.  
Control of NPC differentiation is necessary to use stem cells in a regenerative framework such as a 
conduit loaded with NPCs.  The different methodologies presented here altered NPC differentiation 
into all neural phenotypes possible.  Nano-scale topography decreased the differentiation into astro-
cytes.  A combination of microscale topography, ECM proteins, and soluble factors increased 
differentiation into oligodendrocytes.  Finally, a continuous EF increased the differentiation into early 
neurons.  This creates opportunities to improve and combine these different cues to obtain greater 
fractions of the desired cell types. 
Nano-scale, unlike microscale topography, altered differentiation of NPCs.  A smaller percentage of 
NPCs differentiated into astrocytes on 60 nm nanotubes compared to planar substrates.  Although 
the decrease was not drastic, it indicates that ordered nanotubes can be used to control NPC differ-
entiation.  Culturing NPCs on a range of nanotube diameters would determine if NPC changes are 
dependent on pore size like they were for MSCs238.  After determining the range of useful pore sizes, 
a flexible and biodegradable material with controllable pore dimensions could potentially be created 
and incorporated into conduits for nerve repair.  If successful, NPC differentiation into a desirable 
phenotype would be controlled by pore size.  
We have shown for the first time that continuous EFs in vitro alter NPC differentiation.  A continuous 
437 mV/mm EF caused NSCs to directionally align and increase their differentiation into early neu-
rons.  If the EF strength were decreased, the magnitude of changes observed would likely decrease, 
as demonstrated for hippocampal neurons by Yao et.  al. 274, 293.  EFs of 100, 200 and 300 mV/mm 
should be investigated for both the alternating and continuous EF treatment of NPCs to determine 
dependence on EF strength.  Nevertheless, the control of NPC alignment and differentiation prior to 
or after transplantation would be one application of EF treatment.  EF application would be useful to 
control migration over small distances (less than 4 mm) and to cause alignment once NPCs are im-
planted.  The use of stem cells combined with EF treatment during transplantation however has not 
been attempted.  Thus, the development of EF uses and bioelectrical interactions in neural tissue 
engineering should continue.   
Culturing with a single cue does not necessarily cause changes in NPCs.  For example, NPCs alone 
on micropatterned substrates did not influence differentiation or proliferation, but when combined with 
different extracellular matrix proteins (e.g. - ECL) and soluble molecules, the differentiation into oli-
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godendrocytes was increased significantly.  Thus, a combination of physical, biological and electric 
cues may prove to be a valuable methodology to control stem cells in the creation of nerves in vitro.  
Combinations of nanotubes and different extracellular matrix proteins are possible 100, 102, 232.  Also, 
polymers that are electrically conductive have been developed and used in culture of PC12 cells 159.   
Such a combination could be used to make a conduit with concentric or overlapping layers, spaced 
apart, to allow for stem cell plating.  Each layer could be tailored to provide cues to augment differen-
tiation into a specific cell type.  For example cues that promote differentiation into neurons and 
oligodendrocytes could be alternated by layer.  Oligodendrocytes would then be available to ensheath 
neurons with myelin.  Alignment in the appropriate orientation within the conduit would be controlled 
by nano or micro scale structure.  Finally, the conduit could be placed onto a culture system that 
would allow for EF stimulation to mimic endogenous EFs during development, which are necessary 
for proper nerve formation.  The alignment observed in the continuous EF was perpendicular to the 
EF vector.  Thus, the conduit would have to be placed perpendicularly to the EF for the processes of 
NPCs to grow along the length of the conduit.  In this way a conduit with cultured nerve tissue could 
be used to repair the peripheral or central nervous system, instead of having to use nerve grafts from 
donor locations within the patient.  
However, despite all these advances, controlling stem cell behavior is still challenging.  Vast optimiza-
tion of individual and combined cues to achieve total control of stem cells will be very tedious but 
necessary.  Otherwise the use of stem cells could exacerbate the problems that cell based therapies 
are meant to treat.  Using the appropriate cues and developing implantable, three dimensional scaf-
folds on which stem cells will behave as desired, will pose a further challenge.  Once in vivo it will be 
difficult to control stem cell behavior because of the external stimuli from surrounding tissue.  Con-
duits could be used to isolate and provide the desired cues to stem cells.  Despite all the challenges, 
the investigation of external cues is a necessary, but first step, to develop the therapeutic approaches 
of the future.   
If the mechanism involved in the external control of stem cells were elucidated, optimizing of cues or 
combinations of those would be greatly facilitated.  Understanding the mechanistic response to exter-
nal cues would facilitate the creation of materials or procedures that imitate conditions in vivo.  Most 
external stimuli interact with cells via membrane receptors and channels on cells.  These channels or 
receptors can lead to changes in the internal ionic concentration.  Fluorescent dyes used to investi-
gate the ionic changes within cells (i.e. – Fluo-4 A.M, used in Ca2+ imaging) should be investigated, 
especially during EF treatment.  Since, the ions are affected by the EF,  using fluorescent dyes spe-
cific for certain ions, the type of ionic flow most affected by EF could be determined.  Additionally, 
blockage of specific channels or receptor pharmaceutically combined with fluorescent ionic imaging 
would further elucidate the specificity of the EF effects on ionic channels.  Visualizing the ionic flow in 
and out of the NPCs and determining changes in differentiation in different EFs would allow the ob-
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servation of a link between increased differentiation into a phenotype and changes in ionic activity.  In 
the EF parameters that would maximize the differentiation (e.g. – into neurons as observed here, or 
to another phenotype) due to an EF could be tuned.  
The use of EF to treat an entire population of NPCs has been used here, but selective local and spa-
tially controlled stimulation can be delivered using micro electrode arrays.  Flexible microelectrode 
arrays such as those used in retinotopic activation of the visual cortex294, could be developed to 
house and stimulate NPCs for use in nerve repair.  Furthermore, nerve activity and regeneration 
could be monitored with such devices295.  Applying an electrical stimulus would potentially control the 
differentiation of transplanted stem cells to help improve the mild regenerative effect of electrical 
stimulation applied to the nervous system133. 
Responses to individual or combined external stimuli were determined, here, for NPCs from adult 
rats.  One ponders if the responses would be the same for human NPCs.  Furthermore, would the 
changes be similar for stem cells that are less committed to a specific lineage, such as pluripotent 
stem cell?  The possibility of testing human pluripotent stem cells derived autologously instead of 
from embryos now exists7.  Thus, testing these approaches using human autologous pluripotent stem 
or adult stem cells would be most applicable to clinically relevant situations.   
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